Acute Pro-inflammatory Immune Response Following Different Resistance Exercise Protocols in Trained Men by Wells, Adam
University of Central Florida 
STARS 
Electronic Theses and Dissertations, 2004-2019 
2015 
Acute Pro-inflammatory Immune Response Following Different 
Resistance Exercise Protocols in Trained Men 
Adam Wells 
University of Central Florida 
 Part of the Education Commons, and the Exercise Physiology Commons 
Find similar works at: https://stars.library.ucf.edu/etd 
University of Central Florida Libraries http://library.ucf.edu 
This Doctoral Dissertation (Open Access) is brought to you for free and open access by STARS. It has been accepted 
for inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more 
information, please contact STARS@ucf.edu. 
STARS Citation 
Wells, Adam, "Acute Pro-inflammatory Immune Response Following Different Resistance Exercise 








ACUTE PRO-INFLAMMATORY IMMUNE RESPONSE FOLLOWING DIFFERENT 




ADAM JOHN WELLS 
BS University of West Florida, 2008 
MS University of Central Florida, 2012 
 
 
A dissertation submitted in partial fulfillment of the requirements  
for the degree of Doctor of Philosophy  
in the College of Education and Human Performance  














































The successful regeneration of muscle tissue is dependent upon the infiltration of 
phagocytic CD14++CD16- monocytes that support the proliferation and differentiation of 
myogenic precursor cells. Physiologically, the magnitude of the cellular response following 
resistance exercise is dictated by the level of receptor expression on the plasma membrane of the 
monocyte, as well as the secretion of their cognate ligands from tissue resident cells.  However, 
it remains unclear whether the innate pro-inflammatory immune response varies with different 
resistance training protocols, and how it may impact recovery and the muscle remodeling 
process. Therefore, the purpose of this investigation was to examine temporal changes in the 
expression of chemotactic and adhesion receptors following an acute bout of high-volume, 
moderate-intensity (VOL) versus high-intensity, low-volume (HVY) lower-body resistance 
exercise in experienced, resistance trained men. Changes in receptor expression were assessed in 
conjunction with plasma concentrations of MCP-1, TNFα, and cortisol. Ten resistance-trained 
men (90.1 ± 11.3 kg; 176.0 ± 4.9 cm; 24.7 ± 3.4 yrs; 14.1 ± 6.1% body fat) performed each 
resistance exercise protocol in a random, counterbalanced order. Blood samples were obtained at 
baseline (BL), immediately (IP), 30 minutes (30P), 1 hour (1H), 2 hours (2H), and 5 hours (5H) 
post-exercise. Analysis of target receptor expression on CD14++CD16- monocytes was completed 
at BL, IP, 1H, 2H and 5H time points via flow cytometric analysis. Plasma concentrations of 
myoglobin, and LDH AUC were significantly greater following HVY compared to VOL (p = 
0.003 and p = 0.010 respectively). Changes in plasma TNFα, MCP-1, and expression of CCR2, 
CD11b, and GCR on CD14++CD16- monocytes were similar following HVY and VOL. When 
collapsed across groups, TNFα was significantly increased at IP, 30P, 1H and 2H post-exercise 
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(p = 0.001 – 0.004), while MCP-1 was significantly elevated at all post-exercise time points (p = 
0.002 – 0.033). CCR2 expression was significantly lower at IP, 1H, 2H and 5H post-exercise (p 
= 0.020 – 0.040). In contrast, CD11b receptor expression was significantly greater at 1H relative 
to BL (p = 0.001), while GCR expression was not significantly different from baseline at any 
time point. As expected, plasma cortisol concentrations were significantly higher following VOL 
compared to HVY (p = 0.001), although this did not appear to be related to changes in receptor 
expression. Plasma testosterone concentrations and TNFr1 receptor expression did not appear to 
be affected by resistance exercise. Our results do not support a role for cortisol in the modulation 
of CCR2 receptors in vivo, while the degree of muscle damage does not appear to influence 
plasma concentrations of TNFα, or MCP-1. It is therefore likely that both HVY and VOL 
protocols constitute an exercise stimulus that is sufficient enough to promote a robust pro-
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CHAPTER I: INTRODUCTION 
 
Changes in acute program variables (i.e., intensity, volume and rest) during resistance 
training  may result in a different physiological stimulus to the muscle (Bogdanis, 2012). If the 
stimulus is of significant magnitude, often at a level that is greater than the muscle is accustomed 
to, significant damage to the recruited musculature may be observed (Clarkson & Hubal, 2002). 
Damaged myofibers subsequently undergo either apoptotic or necrotic cell death (Wynn & 
Barron, 2010), leading to the production of cellular debris. Recent evidence suggests that the 
presence of cellular debris may interfere with muscle regenerative processes, acting as a physical 
barrier that prevents myoblasts from efficiently contacting and fusing with existing myofibers 
(H. Lu, Huang, Ransohoff, & Zhou, 2011). This has been reported to result in delayed and 
impaired muscle regenation, characterized by increased fibrosis (Shen, Li, Tang, Cummins, & 
Huard, 2005), and fat infiltration (Summan et al., 2006; Wang et al., 2014). Consequently, the 
removal of cellular debris following myotrauma appears to be important for successful muscle 
regeneration.  
The clearance of cellular debris is accomplished by specialized phagocytic macrophage 
cells that possess specific receptors dedicated to the envelopment of pathogens and opsonized 
tissue (Aderem & Underhill, 1999). Phagocytic macrophages are derived from circulating 
CD14++CD16- monocytes, which are recruited to the site of muscle damage (Soehnlein & 
Lindbom, 2010; Wermuth & Jiminez, 2015). Upon entry into the tissue, cytokines and 
chemokines produced by local innate immune cells drive monocyte differentiation towards the 
pro-inflammatory macrophage (M1) phenotype (Ginhoux & Jung, 2014; Wermuth & Jiminez, 
2015), which support the clearance of opsonized tissue and the proliferation of myogenic 
precursor cells (MPC’s) (Arnold et al., 2007; Saclier et al., 2013). Abrogation of C-C chemokine 
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receptor 2 (CCR2) and/or endothelial adhesion receptor CD11b on CD14++CD16- monocytes has 
been shown to result in an attenuated macrophage accumulation, and subsequent prevention of 
muscle regeneration (Arakawa et al., 2010; Arnold et al., 2007; Brodmerkel et al., 2005; 
Chazaud et al., 2003; Contreras-Shannon et al., 2007; Mesri, Plescia, & Altieri, 1998; Ochoa et 
al., 2007; H. Rosen & Gordon, 1987; Schenkel, Mamdouh, & Muller, 2004; Tsou et al., 2007; 
Volpe et al., 2012; Warren et al., 2004; Willenborg et al., 2012). Therefore, the successful 
infiltration of monocytes into damaged tissue is paramount for optimal tissue remodeling.   
CD14++CD16- monocytes are reported to possess gene enrichment in areas that make 
them particularly receptive to environmental stimuli. These stimuli include bacterial components, 
toxins, drugs, hypoxia, nutrient levels, and hormones (Wong et al., 2011). Resistance exercise 
alone is a potent stimulus for acute increases in the concentrations of circulating hormones 
(Smilios, Pilianidis, Karamouzis, & Tokmakidis, 2003). Perturbations to the systemic hormone 
profile may subsequently dictate the timing and magnitude of the inflammatory response (Kiess 
& Belohradsky, 1986; Walsh et al., 2011), which in turn may lead to altered tissue adaptation. 
Glucocorticoids in particular have been implicated with innate immune-regulation, potentiating 
an up-regulation in the expression of chemotactic receptor CCR2 on human monocytes in vitro 
(Okutsu, Suzuki, Ishijima, Peake, & Higuchi, 2008; Penton-Rol et al., 1999; Pettersson et al., 
2005). High-volume resistance exercise protocols may stimulate a differential pattern of receptor 
expression, since these protocols are often reported to result in greater circulating cortisol 
concentrations compared to low-volume resistance exercise (Ahtiainen, Pakarinen, Kraemer, & 
Hakkinen, 2003; Kraemer & Ratamess, 2005). Nevertheless, a comparison of monocyte cell 
surface protein expression following different resistance training protocols, to our knowledge, 
has not yet been conducted.  
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The presence of a number of other ligands within the circulation may also regulate the 
expression of specific cell surface receptors. For example, both monocyte chemotactic protein – 
1 (MCP-1) and tumor necrosis factor alpha (TNFα) have been shown to modulate both CCR2 
and CD11b receptor expression on leukocytes (Gamble, Harlan, Klebanoff, & Vadas, 1985; 
Montecucco et al., 2008; K. Takahashi et al., 2003; Vaddi & Newton, 1994; Weber et al., 1999). 
However, the effect of different resistance exercise protocols on circulating MCP-1 and TNFα 
levels is not known. It remains unclear whether the innate pro-inflammatory immune response 
varies with different resistance training protocols, and how it may impact recovery and the 
muscle remodeling process. Therefore, the purpose of this investigation was to examine temporal 
changes in the expression of chemotactic and adhesion receptors following an acute bout of high-
volume, moderate-intensity (VOL) versus high-intensity, low-volume (HVY) lower-body 
resistance exercise in experienced, resistance trained men. Specifically, the expression of tumor 
necrosis factor receptor-1 (TNFr1), C-C chemokine 2 (CCR2), cluster of differentiation 
(CD)11b, and glucocorticoid receptor (GCR) were assessed. Changes in receptor expression 
were assessed in conjunction with changes to plasma concentrations of MCP-1, TNFα, and 










CHAPTER II: LITERATURE REVIEW 
 
Skeletal muscle demonstrates a profound capacity to adapt to an array of physiological 
demands (Hawke & Garry, 2001). Episodic bouts of muscle contraction are potent stimuli in this 
regard; which under optimal conditions, leads to the remodeling and functional adaptation of 
skeletal muscle tissue in response to mechanical stress (Egan & Zierath, 2013; Hawke & Garry, 
2001). Manipulation of the mechanical stimulus has been suggested to impart varying degrees of 
skeletal muscle adaptation (Kraemer & Ratamess, 2005). This stimulus is primarily modulated 
through changes to acute program variables such as exercise intensity, volume and rest intervals, 
which evoke distinct mechanical and biochemical responses that subsequently lead to contrasting 
contractile phenotypes (Hornberger, 2011).  
Traditionally, resistance training paradigms are divided into either high-intensity or high-
volume protocols. High-intensity protocols typically involve heavy loads [(≥ 85% repetition 
maximum (1RM)], low volumes (2-6 sets; ≤ 6 repetitions), and longer rest intervals (3-5 
minutes), while high-volume protocols typically involve more moderate intensities [< 85% 
1RM)], higher volumes (3-6 sets; 8-12 repetitions), and shorter rest intervals (30 – 90 seconds) 
(Bird, Tarpenning, & Marino, 2005; Tan, 1999). High-intensity, low-volume protocols are 
thought to result in greater strength gains, which may be related to the recruitment of high-
threshold motor units inherent with heavier loading (Kraemer & Ratamess, 2004; Sale, 1987). In 
contrast; high-volume, moderate-intensity protocols are generally thought to stimulate muscle 
hypertrophy, which may be mediated, in part, by concomitant elevations in systemic hormones 
that are thought to augment the anabolic response (Crewther, Cronin, Keogh, & Cook, 2008; 
McCaulley et al., 2009; Smilios et al., 2003). Notwithstanding, the optimal configuration of 
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program variables for the purpose of maximizing strength and/or muscle growth remain unclear 
(Adams & Bamman, 2012). However, it is likely that skeletal muscle regeneration/adaptation 
depends upon the finely coordinated interactions of a number of distinct biological systems that 
work together for the resolution of tissue homeostasis (Kharraz, Guerra, Mann, Serrano, & 




Adult skeletal muscle fibers are terminally differentiated cells (Hawke & Garry, 2001). 
Because the nuclei within these fibers are post-mitotic, myogenesis depends primarily upon a 
population of satellite cells that are crucial for muscle growth and repair (Bondesen, Mills, 
Kegley, & Pavlath, 2004). Under conditions of homeostasis, satellite cells remain in a non-
proliferative quiescent state, and are physically distinct from adult myofibers due to their 
confinement to indentations between the basal lamina and sarcolemma of the muscle fiber 
(Hawke & Garry, 2001). However, in response to myotrauma, quiescent satellite cells become 
activated (at which stage they are refereed to as MPC’s), and begin to proliferate. While a small 
subset of activated satellite cells subsequently return to quiescence in a process of self-renewal 
(Brack & Rando, 2012; Charge & Rudnicki, 2004), most satellite cells will differentiate and fuse 
to damaged myofibers for the purpose of restoring tissue integrity and function (Martin & Lewis, 
2012). The satellite response has been recently associated with the extent of training induced 
muscle hypertrophy (Bellamy et al., 2014). This process, decribed in detail by Charge and 
colleagues (2004), is illustrated in Figure 1. Following damage to the myofiber, activated 
quiescent satellite cells begin to proliferate, allowing for expansion of the myogenic cell 
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population (A). At the molecular level, activation of MPC’s in response to myotrauma is 
mediated by the up-regulation of a number of muscle regulatory factors (MRF’s), which lead to 
the commitment of satellite cells to the myogenic lineage (Sabourin & Rudnicki, 2000). 
Following the proliferative phase, committed satellite cells (myoblasts) travel to damaged 
myofibers in response to chemical stimuli (chemotaxis) (B), where they fuse to damaged 
myofibers and become terminally differentiated mononucleated myocytes (Hindi, Tajrishi, & 
Kumar, 2013) (C). During fusion, myoblasts provide new myonuclei to the existing myofibers, 
which grow to resemble the original myofiber. As regeneration progresses, donated myonuclei 
coalesce towards the center of the regenerated myofiber (D) resulting in the characteristic 
centronucleated appearance (Bosurgi, Manfredi, & Rovere-Querini, 2011). As regeneration is 
completed, these myonuclei migrate to the periphery of the fiber and begin to resemble normal 





Figure 1. Satellite cell response to myotrauma.  
Adapted from Myogenic satellite cells: physiology to molecular biology. Hawke and Garry 
(2001). Included with permission. 
 
While it is widely accepted that the satellite cell response is fundamental for the 
reconstitution of muscle integrity following myotrauma, skeletal muscle regeneration is a 
functionally complex phenomenom. In addition to the role of MPC’s, many other cell types play 
a role in optimizing the regenerative processes. These cells include endothelial cells, interstitial 
cells, mesenchymal progenitors, fibro/adipogenic progenitors, and inflammatory cells (Ceafalan, 
Popescu, & Hinescu, 2014). Alongside satellite cells, inflammatory cells appear to be essential 
for successful muscle regeneration (Kharraz et al., 2013). In particular, it is widely recognized 
that macrophages execute a critical role in muscle repair (Brunelli & Rovere-Querini, 2008; 
Robertson, Maley, Grounds, & Papadimitriou, 1993; Saclier et al., 2013; Tidball & Wehling-
Henricks, 2007; Wang et al., 2014).  
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Macrophages and Muscle Repair 
 
Resistance exercise results in damage to parenchymal cells (myofibers), which 
subsequently undergo either apoptotic or necrotic cell death (Wynn & Barron, 2010). The 
clearance of these apoptotic/necrotic cells (cellular debris) is accomplished by specialized 
phagocytic macrophage cells that possess specific receptors dedicated to the envelopment of 
pathogens and cellular debris (Aderem & Underhill, 1999). The removal of cellular debris 
following tissue damage appears to be a critical event that directly mediates muscle regeneration 
(Bosurgi et al., 2011). Recent evidence suggests that the presence of necrotic fibers may interfere 
with muscle regenerative processes, acting as a physical barrier that prevents myoblasts from 
efficiently contacting and fusing with existing myofibers (H. Lu et al., 2011). Consistent with 
this, impaired muscle regeneration is reported to be prevalent following in vitro macrophage 
depletion (Brunelli & Rovere-Querini, 2008), indicating that the macrophage-mediated removal 
of cellular debris is likely critical for optimal tissue regeneration. However, upon the cessation of 
phagocytosis, macrophages remain present in regenerating areas, often in high numbers, and are 
tightly associated with MPC’s and young regenerating myofibers (Saclier, Cuvellier, Magnan, 
Mounier, & Chazaud, 2013). Additionally, depletion of intramuscular macrophages following 
complete phagocytosis has been shown to result in reduced muscle fiber size during recovery 
from myotrauma (Arnold et al., 2007). This indicates that macrophages may have the ability to 
promote muscle regeneration independent of phagocytic function. 
In vitro studies suggest that macrophages directly support MPC growth via the secretion 
of soluble mitogenic factors (Chazaud et al., 2003; Merly, Lescaudron, Rouaud, Crossin, & 
Gardahaut, 1999). In particular, macrophage derived insulin-like growth factoe-1 (IGF-1) 
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appears to have a role in mediating tissue repair. IGF-1 exerts its function via the 
phosphorylation of Akt which leads to MPC proliferation and myoblast differentiation (Engert, 
Berglund, & Rosenthal, 1996; Schiaffino & Mammucari, 2011). Following myotrauma, 
macrophage accumulation has been shown to correlate with an up-regulation of both mRNA and 
protein expression of IGF-1 (Heinemeier et al., 2009; H. Lu et al., 2011). Additionally, it has 
been reported that impaired muscle regneration following macrophage depletion is associated 
with a concomitant decrease in IGF-1 mRNA within the muscle (Summan et al., 2006). Further, 
the recently described protective effect of macrophages against myotube atrophy (N. A. Dumont 
& Frenette, 2013) is abolished following administration of an anti-IGF-1 antibody treatment (N. 
Dumont & Frenette, 2010). Therefore, it is reasonable to suggest that the role of macrophages in 
skeletal muscle regeneration may be mediated, at least in part, by the production of mitogenic 
factors including IGF-1. 
Recent studies have established that macrophages exert different effects on MPC’s, 
dependent upon their polarization to either the pro-inflammatory (M1) or anti-inflammatory 
(M2) phenotype. M1 macrophages appear to stimulate MPC proliferation and inhibit their fusion 
(Arnold et al., 2007; Saclier et al., 2013), while M2 macrophages appear to stimulate myogenesis 
by promoting the terminal differentiation of myoblasts and the formation of large myotubes 
(Saclier et al., 2013). M2 macrophages are likely derived from M1 macrophages and thus 
represent a latter stage of inflammatory macrophage differentiation. It has been posited that the 
removal of cellular debris may serve as a key signal prompting the functional shift in 
macrophage phenotype (Arnold et al., 2007; Rigamonti, Zordan, Sciorati, Rovere-Querini, & 
Brunelli, 2014; Tidball & Villalta, 2010).  
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Macrophages have been associated with the “rescuing” of myotubes from apoptosis 
following skeletal muscle injury (Chazaud et al., 2003; Lesault et al., 2012; Sonnet et al., 2006). 
The addition of macrophages to primary MPC cultures in vitro appears to lead to an inhibition of 
spontaneous myoblast and myotube apoptosis that coincides with the enhanced expression of 
anti-apoptotic proteins and activation/phosphorylation of ERK1/2 and Akt pathways (Sonnet et 
al., 2006). It is possible that macrophage derived IGF-1 may mediate these anti-apoptotic effects, 
since IGF-1 is known to facilitate the inhibition of the foxhead box O (FoxO) apoptotic signaling 
(Stitt et al., 2004; Zhang, Tang, Hadden, & Rishi, 2011). FoxO transcription factors mediate cell 
cycle arrest, DNA repair and apoptosis (Lam, Francis, & Petkovic, 2006). However; to our 
knowledge, the role of macrophage derived IGF-1 in mediating FoxO signalling has not been 
addressed. Nevertheless, macrophages may exert their anti-apoptotic fuinction through 
mechanisms independent of IGF-1 signalling. DNA microarray analyses indicates that MPCs 
constitutively express four cell-to-cell molecular adhesion receptors, all of which are functionally 
active and responsive to counterligands expressed by human macrophages. Blockade of any one 
of these adhesion receptors results in the inhibition of the beneficial effect of macrophages on 
MPC survival. Therefore, the delivery of anti-apoptotic signals appears to be mediated by cell-
to-cell contact between macrophages and MPCs (Chazaud et al., 2003; Sonnet et al., 2006). 
These receptor systems are more strongly expressed by myotubes (multinucleated differentiated 
myogenic cells) that are more protected from apoptosis compared with undifferentiated 
myoblasts, suggesting that macrophages could help protect these cells until they establish a final 
association with the extracellular matrix (Chazaud et al., 2009).  
Current evidence suggests that macrophages exert their effect in three ways: 1. via the 
phagocytosis of opsonized cellular debris; 2. via production of soluble factors that globally 
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stimulate MPC proliferation and differentiation; and 3. via delivery of anti-apoptotic signals 
through direct cell contact with MPCs (Aderem & Underhill, 1999; Chazaud et al., 2003; Sonnet 
et al., 2006). The influence of macrophages in the resolution of tissue damage is depicted in 
Figure 2.  Briefly, the tibialis anterior and quadriceps muscles of two month old C57BL/6 mice 
were injected with cardiotoxin (CTX) to induce muscle damage. Mice were subsequently treated, 
or not, with clodronate-containing liposomes to deplete macrophages, and were subsequently 
sacrificed 15-days following CTX injection. Histochemical analysis of the harvested muscle 
tissue was performed at day 15. Panel A depicts the healthy muscle of untreated control mice. 
Myonuclei (dyed in blue) are confined to the periphery of the myofibers, indicating a healthy 
mature muscle cell. Panel B depicts the muscle tissue of macrophage-competent mice 15-days 
post-CTX injection. Centronucleated fibers are evident throughout the section indicating 
effective and almost complete regeneration. Panel C depicts the muscle tissue of marophage 
depleted mice 15-days post-CTX injection. Muscle regeneration is significantly impaired and 
degenerative fibers and cell remnants persist.  
 
 
Figure 2. Macrophages and tissue regeneration.  
Adapted from Macrophages in injured skeletal muscle: A perpetuum mobile causing and limiting 
fibrosis, prompting or restricting resolution and regeneration. Bosurgi, Manfredi and Rovere-







Skeletal muscle has been shown to contain a large population of resident macrophages 
(Honda, Kimura, & Rostami, 1990). However, macrophages are also known to originate from 
circulating monocytes (Kumar & Jack, 2006). In light of this, previous studies have attempted to 
examine the role of both resident and monocyte derived macrophages in muscle regenerative 
processes following acute skeletal muscle injury (McLennan, 1993; McLennan, 1996). The 
origin of macrophages involved in the removal of degenerating muscle fibers has previously 
been investigated in vivo using ectodermal dysplasia antibodies ED1 (CD68), ED2 (CD163), and 
ED3 (CD169), as well as RM-1 and W3/13 (CD43) monoclonal antibodies (Honda et al., 1990; 
McLennan, 1993; McLennan, 1996). These antibodies are specific to mononuclear phagocyte 
system (MPS) antigens, and thus can be utilized to differentiate and examine macrophage 
phenotype in various tissues. The ED1 antibody is expressed by monocytes and monocyte 
derived pro-inflammatory macrophages. ED2 and ED3 antibodies bind to certain subsets of 
resident macrophages, including those in skeletal muscle, without binding to pro-inflammatory 
macrophages, dendritic cells, or their monocytes precursors (McLennan, 1993). RM-1 antibodies 
are also specific to monocytes and a sub-population of resident macrophages, while W3/13 
antibodies are specific to neutrophils. Staining of degenerating muscle fibers with monoclonal 
antibody antigens specific to these macrophage and neutrophil phenotypes have enabled the 
identification of cell subtypes involved with muscle regeneration using immunohistochemistry. 
Additionally, the spatial and temporal distributions of these cells following acute muscle injury 
have been characterized (McLennan, 1993; McLennan, 1996).  
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Observational studies indicate that different subtypes of hemopoietic cells are attracted to 
a lesion by distinct signals, and have differing functions in the process of muscle regeneration. 
According to these observations, W3/13 neutrophils are the first cells to penetrate and leave 
damaged tissue (Fielding et al., 1993; McLennan, 1996). Neutrophils are apparent in the 
epimysium overlying tissue damage from freeze lesioning at 1 hour post-injury, and are widely 
distributed throughout damaged tissue 7 hours following freeze lesioning of the tibialis anterior 
muscle in Wistar rats (McLennan, 1996). However, these cells are rarely observed to penetrate 
into muscle fibers during the regenerative process (McLennan, 1996). While their exact function 
is not clearly defined, recent evidence suggests that the role of neutrophils is to initiate the repair 
process that becomes subsequently managed by macrophages (Butterfield, Best, & Merrick, 
2006). This may be achieved through the generation of soluble factors such as proteases and 
reactive oxygen species (ROS) (Pizza, McLoughlin, McGregor, Calomeni, & Gunning, 2001; G. 
M. Rosen, Pou, Ramos, Cohen, & Britigan, 1995). These factors appear to contribute to 
secondary tissue damage (Kharraz et al., 2013; Nguyen, Lusis, & Tidball, 2005), which may 
serve to modify the intramuscular environment in preparation for the phagocytosis of tissue 
debris by macrophages. In vivo analysis in human subjects confirm the temporal appearance of 
neutrophils observed in the murine model. Following 45 minutes of downhill running in 
untrained men, Fielding and colleagues (1993) reported a significant infiltration of neutrophils to 
the exercised tissue within an hour of exercise cessation. 
ED2+ and ED3+ macrophages, although abundant throughout healthy muscle tissue, do 
not appear to be present within degenerating muscle fibers (McLennan, 1993; McLennan, 1996). 
ED2+ macrophages reportedly accumulate in the epimysium and perimysium surrounding tissue 
lesions, but do not penetrate into the lesion until extensive phagocytosis has already occurred 
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(usually 1 or 2 days). Pursuant to penetration, ED2+ cells are concentrated in the regenerating 
connective tissues and empty remnants of phagocytized fibers, but are rarely observed to invade 
necrotic tissue, even when immediately adjacent to it (McLennan, 1993; McLennan, 1996). This 
suggests that this type of macrophage has a specialized function which is unrelated to removal of 
damaged tissue.  
Undamaged muscle tissue appears to be essentially devoid of ED1+ macrophages. 
However; following damage, a small number of ED1+ cells (monocyte derived cells) appear 
within an hour of tissue lesioning, with subsequent cellular infiltration of these cells becoming 
apparent within 3 hours (McLennan, 1996). ED1+ macrophages subsequently predominate 
during the initial response to skeletal muscle damage, taking charge in the clearance of 
opsonized cellular debris (Brigitte et al., 2010). Their absence from healthy tissue suggests that 
ED1+ pro-inflammatory macrophages are derived from monocytes that enter the tissue from 
adjacent arterioles in response to muscle damage. This notion is supported by more recent 
evidence that suggests that MPCs depend on the support of stromal cells (supportive cells), 
including monocyte/macrophages, to develop their myogenic program (Seale, Asakura, & 
Rudnicki, 2001; Spradling, Drummond-Barbosa, & Kai, 2001). Consistent with this, all 
phagocytic macrophages are reported to be ED1+/ED2-/ED3-. MPCs in vitro, appear to 
selectively and specifically recruit monocytes through the endothelium in a dose-dependent 
manner (Chazaud et al., 2003). This recruitment varies according to myogenic maturation, 
whereby chemotactic activity progressively declines during the later stages of myogenic 
differentiation, after peaking immediately following MPC release from quiescence. Furthermore, 
the depletion of circulating monocytes in mice at the time of muscle injury has been shown to 
completely prevent muscle regeneration (Arnold et al., 2007), reinforcing the notion that 
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circulating blood monocytes supply the peripheral tissues with macrophage precursors (Serbina, 
Jia, Hohl, & Pamer, 2008).  
 
Human Monocyte Subsets 
 
Monocytes constitute approximately 10% of the total circulating leukocyte population in 
humans (Italiani & Boraschi, 2014). Peripheral circulating monocytes exhibit morphological 
heterogeneity, manifested through variations in size, granularity and nuclear morphology 
(Gordon & Taylor, 2005; Strauss-Ayali, Conrad, & Mosser, 2007; Yona & Jung, 2010). 
However, in terms of function, peripheral blood monocytes in humans are characterized based 
upon their differential expression of antigenic markers, rather than their morphological 
characteristics. Derived in the bone marrow from a common Lin1-cKithiCD115+CX3CR1+Flt3+ 
progenitor cell (macrophage and DC precursor; MDP) (Fogg et al., 2006), circulating human 
monocytes were initially identified based upon their high expression of CD14 antigen (Griffin, 
Ritz, Nadler, & Schlossman, 1981). Subsequent research has since determined that a number of 
sub-populations of human peripheral blood monocytes exist, which are distinguishable based 
upon the differential expression of CD14 and CD16 antigens. Until recently, monocyte 
heterogeneity was mostly understood based upon the categorization of 2 subpopulations; the 
CD16- classical monocyte, and the non-classical CD16+ monocyte. However, a panel of leading 
experts in monocyte biology recently proposed consensus nomenclature for the re-classification 
of human monocytes into three distinct subsets, which has since been approved by the 
International Union of Immunological Societies (L. Ziegler-Heitbrock et al., 2010). These 
subpopulations were subsequently redefined as classical (CD14++CD16-), non-classical 
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(CD14+CD16++) and intermediate (CD14++CD16+) monocytes. However, this characterization is 
still in its infancy. Consequently, for the purposes of this review, monocyte heterogeneity will be 
discussed in relation to classical (CD14++CD16-) and non-classical (CD14+CD16++) monocyte 
only. 
To date, the functional characteristics of human monocyte subsets have been primarily 
investigated through the examination of murine models as a surrogate for the study of human 
monocyte behavior in vivo (Geissmann, Jung, & Littman, 2003; Gordon & Taylor, 2005; L. 
Ziegler-Heitbrock et al., 2010). Although monocyte subsets in humans and mice are not precisely 
analogous, their differentiation and contribution to immune defense appear to be similar (Belge 
et al., 2002; Ingersoll et al., 2010; Shi & Pamer, 2011). Consequently, the murine model of in 
vivo monocyte behavior has provided significant insight into the functional roles of monocyte 
subsets in humans. 
 
Murine Monocyte Heterogeneity 
 
Murine monocyte subsets are not distinguishable by CD14 and CD16 antigen expression 
(Serbina et al., 2008), but instead are recognized as CD115+ (macrophage colony stimulating 
factor [M-CSF] receptor), CD11b+, and F4/80int blood cells (Ingersoll et al., 2010). Two subsets 
of monocytes have been described in mice, which can be identified based upon their relative 
expression of the pro-inflammatory monocyte marker Ly-6C (Sunderkotter et al., 2004). Ly-6C 
can be identified by flow cytometry using the Gr-1 antibody, which recognizes an epitope of Ly-
6C (Fleming, O'hUigin, & Malek, 1993). It is now accepted that mouse monocyte subsets are 
grouped as Ly-6C+ (further divided as Ly-6Chigh and Ly-6Cmiddle), and Ly-6Clo or Ly-6C- cells 
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(Yang, Zhang, Yu, Yang, & Wang, 2014). Ly-6C+ mouse monocytes are characterized by the 
CX3CR1lowCCR2+CD62L+(L-Selectin) phenotype, and are suggested to correspond to classical 
(CD14++ CD16-) human monocytes (Taylor & Gordon, 2003). Ly-6Chigh and Ly-6Cmiddle subsets 
express high levels of CCR2 and low levels of CX3CR1 (Saederup et al., 2010). MCP-1, an 
inflammatory cytokine, which signals through C-C chemokine receptor 2 (CCR2) on Ly-6C+ 
monocytes, has been suggested to induce a conformational change in the formation of specific 
surface adhesion receptors on these cells, resulting in high-affinity vascular binding and 
subsequent transmigration to areas of tissue damage (Yang et al., 2014). This role is consistent 
with the Ly-6C+ cells pro-inflammatory functions, and potent capacity for phagocytosis (Serbina 
et al., 2008). During early inflammation, Ly-6C+ cells are thought to enter damaged tissue where 
they preferentially differentiate into M1 pro-inflammatory macrophages, which secrete pro-
inflammatory cytokines and exhibit phagocytic and proteolytic inflammatory functions (Ginhoux 
& Jung, 2014). Additionally, the short half-life of Ly-6C+ monocytes (approx. 8 hours), likely 
limits the function of this cell to that of a macrophage precursor (Italiani & Boraschi, 2014).   
Ly-6C- mouse monocytes are characterized by the CX3CR1highCCR2-CD62L-(L-Selectin) 
phenotype, express low levels of CCR2 and high levels of CX3CR1 (Saederup et al., 2010). A 
distinction within mouse Ly-6C- monocytes that corresponds to human non-classical and 
intermediate distinctions not yet been characterized; however, Ly-6C- monocytes are suggested 
to correspond to human CD16+ monocytes (Ingersoll et al., 2010; Taylor & Gordon, 2003). 
Indeed, a recent study demonstrated the presence of FcγR (receptor corresponding to CD16) on 
Ly-6C- monocytes, but not Ly-6C+ monocytes (Santiago-Raber et al., 2009). In comparison to 
the Ly-6C+ monocytes, Ly-6C- monocytes have a circulating half-life of approximately 5-7 days 
(Yona et al., 2013), suggesting that this cell likely has a functional role within the circulation that 
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is distinct from that of the Ly-6C+ monocyte. Previous studies suggest that Ly6C- monocytes are 
recruited to tissue during the latter phase of inflammation, where they subsequently develop into 
resident macrophages (Geissmann et al., 2003), and thus represent the end stage of a distinct 
differentiation path of a common precursor cell. This is consistent with the longer half-life of this 
cell, since this Th2/M2 anti-inflammatory response does not peak until 4 days post-injury 
(Tidball & Villalta, 2010). However, bone marrow derived monocytes in mice appear to be 
exclusively Ly-6C positive (Sunderkotter et al., 2004). Consistent with this, a recent fate 
mapping study provides evidence to suggest that Ly6C+ blood monocytes constitute an 
obligatory steady-state precursor to Ly6C- monocytes, with subsequent maturation of the Ly6C+ 
cell resulting in a dichotomous phenotype (Yona et al., 2013). A similar shift in cell phenotype 
has also been reported in Ly-6C+ monocyte derived M1 pro-inflammatory macrophages (Arnold 
et al., 2007). These cells appear to have the ability to acquire the phenotypic features and 
functional properties of M2 anti-inflammatory macrophages within inflamed skeletal muscle. 
Together, these observations lend credence to the hypothesis that distinct monocyte/macrophage 
subsets represent subsequent maturation stages in a common path of differentiation, which likely 
leads to divergent functional properties (Stansfield & Ingram, 2015). This hypothesis dictates 
that, in the absence of inflammation, Ly-6C+ monocytes differentiate into Ly-6C- monocytes, 
which remain in the circulation for up to two weeks (Yona et al., 2013). While in circulation, the 
primary function of the Ly-6C- cell appears to be patrolling the endothelium and monitoring its 
integrity (Wermuth & Jiminez, 2015). It has also been suggested that in addition to this 
patrolling function, Ly-6C- monocytes may also serve to replenish the resident macrophage 
population (Geissmann et al., 2003). The functional properties of each murine monocyte subset 
are summarized in Figure 3. Briefly, Ly-6C+ monocytes appear to be preferentially and rapidly 
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recruited to sites of injury and infection in response to pro-inflammatory cues such as MCP-1. 
Most inflammatory monocytes are thought to differentiate into macrophages, which are 
important for the clearance of tissue debris and for the resolution of inflammation. In contrast, in 
the absence of inflammation, Ly-6C- monocytes patrol the endothelial surface and coordinates its 
repair via recruitment of neutrophils as required (Ginhoux & Jung, 2014), and are hypothesized 




Figure 3. Development and function of monocyte subsets in mice.  
Monocyte and Macrophage Heterogeneity. Gordon & Taylor (2005). CX3CL1, CX3C-chemokine 
ligand 1 (fractalkine); CCR7, CC-chemokine receptor 7; CCR8, CC-chemokine receptor 8. 






Monocyte Heterogeneity in Humans 
 
In humans, classical monocytes express high levels of CD14 antigen and no CD16 
antigen (Crowe & Ziegler-Heitbrock, 2010; Weber et al., 2000; Yang et al., 2014). These cells 
constitute the most prevalent monocyte population, accounting for approximately 80-95% of 
total monocytes in human blood (Strauss-Ayali et al., 2007; Wong et al., 2011; Yang et al., 
2014). Gene enrichment in gene ontology biologic processes, which enables the delineation of 
unique characteristics that are inherent to monocyte subsets through the analysis of gene 
expression, suggest that classical monocytes exhibit significant enrichment in the categories of 
angiogenesis, wound healing, and coagulation (Wong et al., 2011). Additionally, CD14++CD16- 
cells are reported to respond to bacterial components, toxins, drugs, hypoxia, nutrient levels and 
hormones, while the pro-inflammatory mediators S100A12 and S100A9 and S100A8 (calcium 
binding proteins) are among the top 50 most highly expressed genes for this subset (Wong et al., 
2011). These data suggest that classical monocytes are highly versatile and capable of 
responding to a variety of external cues, making them ideal for mediating tissue repair or 
immune functions. These functions are consistent with the reports of others who suggest that 
macrophages derived from classical monocytes exhibit excellent phagocytic function (Grage-
Griebenow et al., 2000; Grage-Griebenow, Flad, & Ernst, 2001). Further, the early inflammatory 
response appears to be dominated by the selective recruitment of classical monocytes to injured 
tissue (Ingersoll, Platt, Potteaux, & Randolph, 2011; Wermuth & Jiminez, 2015), where they 
infiltrate at sites of damage/inflammation in response to damage associated molecular patterns 
(DAMP’s), and subsequently differentiate into inflammatory M1 macrophages (Soehnlein & 
Lindbom, 2010; Wermuth & Jiminez, 2015)  for the purpose of phagocytizing opsonized cellular 
debris (Yang et al., 2014). This function is further demonstrated through the expression of 
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specific surface adhesion (CD11b) and chemokine receptors (CCR2) (Stansfield & Ingram, 
2015). This pattern of cell surface apparatus suggests that CD14++CD16– monocytes are 
equipped to respond to inflammatory signals, allowing for their subsequent migration and 
adhesion to the endothelial wall in areas of tissue damage (Imhof & Aurrand-Lions, 2004; 
Mantovani, 1999; Starikova, Lebedeva, & Freidlin, 2010). 
Non-classical monocytes are characterized by their relative low expression of the CD14 
antigen, and a high expression of the CD16 antigen. Under the former nomenclature, non-
classical monocytes (consisting of non-classical and intermediate monocytes) accounted for 
approximately 2-11% of the total monocyte population in human blood (Strauss-Ayali et al., 
2007; Yang et al., 2014). More recent research by Wong and colleagues (2011) suggest that non-
classical monocytes account for 9.2% ± 4.4% of total circulating monocytes. These cells are 
considered the major pro-inflammatory monocyte subpopulation and are the major producers of 
tumor necrosis factor in human blood (Belge et al., 2002; Cros et al., 2010; Passlick, Flieger, & 
Ziegler-Heitbrock, 1989; Wong et al., 2011). Similar to Ly-6C- murine monocytes, non-classical 
human monocytes have been observed to demonstrate a patrolling behavior in healthy tissues 
through long-range crawling on the resting endothelium, and thus may represent a marginal pool 
of monocytes. This may allow for rapid tissue invasion in the event of damage or infection 
(Auffray et al., 2007; Cros et al., 2010). However, following strenuous anaerobic exercise, these 
non-classical monocytes have been observed to mobilize from the marginal pool and enter into 
the circulation, contributing to a 4.8 fold increase in circulating cells within an order of minutes 
(Steppich et al., 2000). This compartment shift may be the result of shear stress or an interaction 
with catecholamines (Freidenreich & Volek, 2012), but nevertheless precludes the rapid entry of 
these cells into sites of exercise-induced damage. Consistent with this, the human CD14+CD16++ 
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non-classical subpopulation has been shown to exhibit poor phagocytic capacity (Cros et al., 
2010), and reduced ROS production, which is a key aspect of phagocytic function in the 
destruction of cellular debris (Cros et al., 2010; Szaflarska et al., 2004). This subset of 
monocytes also exhibits higher expression of CX3CR1, a chemokine receptor reported to mediate 
resident macrophage accumulation in non-inflamed tissue (Ancuta et al., 2003; Geissmann et al., 
2003; Landsman et al., 2009), and exhibit significantly lower levels of CCR2, the chemokine 
receptor mediating monocyte chemotaxis during inflammation (Wong et al., 2011). 
Consequently, non-classical monocytes fail to migrate towards the CCR2 ligand MCP-1 (Weber 
et al., 2000). These cells have also been reported to strongly resemble mature tissue resident 
macrophages (H. W. Ziegler-Heitbrock et al., 1993), which is consistent with a two-fold greater 
affinity for the endothelium in the absence of inflammation, compared to the classical monocyte 
(Starikova et al., 2010). Moreover, non-classical monocytes have recently been shown to exhibit 
a significantly lower expression of CD11b receptor compared to classical monocytes (Wong et 
al., 2011), which has been shown to be critical for tissue repair responses following skeletal 
muscle damage (Arnold et al., 2007).  
The exact role of non-classical monocytes remains unclear; however, these cells do not 
appear to be involved in the acute response to tissue inflammation. While recent reviews have 
focused upon characterizing the origin of tissue resident macrophages (Ginhoux & Jung, 2014; 
Italiani & Boraschi, 2014); to date, no study has provided conclusive evidence against a possible 
role for the non-classical monocyte in tissue macrophage homeostasis (Italiani & Boraschi, 
2014). The origin of tissue resident macrophages appears to vary considerably between tissues, 
and while the origin of these cells has been somewhat characterized in CNS, dermis, epidermis, 
lung, heart, kidney, pancreas, liver, spleen and peritoneal tissue (Epelman et al., 2014; Ginhoux 
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et al., 2010; Guilliams et al., 2013; Schulz et al., 2012), the origin of skeletal muscle resident 




Skeletal muscle repair is a tightly regulated process consisting of an initial inflammatory 
response, followed by subsequent regeneration and revascularization of damaged tissue (H. Lu et 
al., 2011; Tidball, 2005). The initial inflammatory response is characterized by a rapid and 
sequential invasion of leukocyte populations for the purpose of reconstituting tissue integrity. 
Members of the chemokine family of chemotactic cytokines play a fundamental functional role 
in this process by directly influencing the vascular migration and accumulation of specific 
leukocytes to sites of tissue injury (Furie & Randolph, 1995; Henningsen, Pedersen, & 
Kratchmarova, 2011). Within healthy skeletal muscle, the chemokine expression profile is fairly 
limited (De Paepe & De Bleecker, 2013); however, in response to tissue damage, the secretion of 
specific chemokines is induced or significantly upregulated within the tissue (Hirata et al., 2003). 
Chemokine effects are mediated via binding with heptahelical receptors located on the plasma 
membrane of leukocytes, which are coupled to GTP binding proteins (Baggiolini & Loetscher, 
2000). Consequently, the trafficking behavior of specific leukocyte subsets during inflammation 
is dependent upon the both the presence of specific chemokines, and the adequate expression of 
its respective receptor.    
Several studies suggest that a number of chemokines, including MCP-1 and MCP-3 
mediate the chemotaxis of classical monocytes to damaged tissue (Charo & Ransohoff, 2006; 
Rossi & Zlotnik, 2000), raising the question as to which ligand the monocyte is in fact 
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responding to. Observational studies report an increase in MCP-1 that parallels the early 
inflammatory response following induced muscle ischemia (Shireman, Contreras-Shannon, 
Reyes-Reyna, Robinson, & McManus, 2006). In accordance, loss of MCP-1 alone via targeted 
disruption of SCYA2 (the gene encoding MCP-1) has been shown to sufficiently impair 
monocyte trafficking in a number of different inflammatory models (B. Lu et al., 1998). These 
findings were corroborated in later work by Shireman and colleagues (2007), where an altered 
inflammatory response, delayed restoration of perfusion, and significant decrements in indices of 
muscle regeneration were observed following femoral artery excision induced muscle damage in 
MCP-1 knockout mice. Nevertheless, selective deletion of MCPs using homologous 
recombination in embryonic stem cells reveal significant deficits in monocyte recruitment in 
both MCP-1 and MCP-3 knockout models (Tsou et al., 2007). This is consistent with the 
observations of others (Jia et al., 2008), highlighting a possible role for MCP-3 in monocyte 
chemotaxis, and a potential synergy between MCP-1 and MCP-3 for the optimal recruitment of 
classical monocytes to damaged tissue.  
Notwithstanding, recent evidence suggests that MCP-1 is in fact the primary chemokine 
required for classical monocyte recruitment, and not MCP-3 (M. Takahashi, Galligan, 
Tessarollo, & Yoshimura, 2009). Takahashi and colleagues (2009) report a marked increase in 
MCP-3 mRNA production following deletion of a 2.3-kb genomic DNA sequence from the 
MCP-1 gene (that resulted in MCP-1 deficiency), which was not apparent in previously 
generated MCP-1 knockout mice (MCP-1-/-) or MCP-1+/+ controls. Comparison of MCP-1 
deficient and MCP-1-/- mice revealed no significant differences in monocyte recruitment, 
indicating that MCP-3 was unable to compensate for the loss of MCP-1 (M. Takahashi et al., 
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2009). It is likely that MCP-3 plays a limited role in monocyte recruitment. Consequently, MCP-
1 signaling appears to be the primary ligand mediating the recruitment of classical monocytes.  
CCR2 signaling appears to have an important role in the recruitment of monocytes to 
injured tissue (B. Lu et al., 1998; Shireman et al., 2006; Shireman et al., 2007). CCR2 is 
considered to be the exclusive receptor of MCP-1 (Charo & Ransohoff, 2006; Gerard & Rollins, 
2001), and while reports suggest that neutrophil and lymphocyte recruitment is similar between 
wild type and CCR2 knockout mice (CCR2-/-) (H. Lu et al., 2011), the mobilization of 
monocytes both from the bone marrow to the blood, and from the blood to the injured tissue, is 
significantly impaired in CCR2-/- mice compared to controls (H. Lu et al., 2011). This 
impairment appears to be directly associated with classical monocytes. Analysis of gene 
expression reveals that CCR2 is almost exclusively expressed by the classical CD14++CD16- 
monocyte population in humans (Wong et al., 2011). Further, selective labeling of monocyte 
subsets indicate that only Ly-6C+ monocytes are recruited to damaged tissue (Arnold et al., 
2007). While the appearance of Ly-6C- monocytes in the blood is reported to be similar between 
CCR2-/- and control mice (H. Lu et al., 2011), both Ly-6C+ and Ly-6C- monocyte/macrophage 
subsets appear to be drastically reduced within the injured muscle of CCR2-/- mice. This provides 
additional evidence favoring the differentiation of Ly-6C+ monocyte derived pro-inflammatory 
macrophages into anti-inflammatory macrophages, in lieu of a secondary recruitment of Ly-6C- 
monocytes in the later stages of tissue repair (Arnold et al., 2007; H. Lu et al., 2011). 
Nevertheless, CCR2-/- mice exhibit a markedly reduced inflammatory response following tissue 
injury, resulting in significantly impaired muscle regeneration, fibrosis, fat infiltration, and 
calcification of the tissue (H. Lu et al., 2011; Warren et al., 2005). These observations are 
consistent with other CCR2 knockout studies, which report marked reductions in  monocyte 
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infiltration, along with concomitant deficits in both muscle regeneration and tissue 
revascularization following injury (Arnold et al., 2007; Brodmerkel et al., 2005; Chazaud et al., 
2003; Contreras-Shannon et al., 2007; Ochoa et al., 2007; Tsou et al., 2007; Volpe et al., 2012; 
Warren et al., 2004; Willenborg et al., 2012). Interestingly, the role of macrophage produced 
IGF-1 in MPC growth discussed earlier, appears to be monocyte derived and dependent upon 
CCR2 signaling (H. Lu et al., 2011). Together, these data suggest that MCP-1/CCR2 signaling is 
critical for classical monocyte egress from the bone marrow (Serbina & Pamer, 2006), and for 
subsequent recruitment from the blood to the tissue, and for optimal tissue regeneration.  
Recent research suggests a role for resident macrophages in orchestrating this immune 
cell response to myofiber injury (Brigitte et al., 2010). Located within the epimysium and 
perimysium of the muscle, resident macrophages appear to contribute to an extensive recruitment 
of neutrophils and monocytes from the circulation through selective secretion of neutrophil and 
monocyte chemotactic proteins. The functional role of resident macrophages in monocyte 
recruitment is consistent with the dramatic reduction in monocyte infiltration observed following 
selective depletion of resident macrophages in injured muscle (Chazaud et al., 2009). The 
processes of monocyte recruitment into skeletal muscle following injury is depicted in figure 4. 
Briefly; following muscle damage, activated myogenic cells secrete a number of chemotactic 
factors, including MCP-1, aimed at monocyte recruitment. However; compared to that of 
myogenic cells, resident macrophage recruitment of monocytes constitutes a substantially more 
robust chemotactic pathway, initiating the recruitment of both neighboring resident macrophages 






Figure 4. Monocyte recruitment into skeletal muscle following injury.  
Dual and beneficial roles of macrophages during skeletal muscle regeneration. Chazaud et al. 
(2009). MDC, macrophage–derived chemokine; MCP-1, monocyte chemoattractant protein 1; 
CX3CL1, fractalkine; VEGF, vascular endothelial growth factor; uPA, urokinase-type 
plasminogen activator. Included with permission from Wolters Kluwer Health; License #: 
3590431459002. 
 
Recent reports suggest that CCR2 does not appear to demonstrate a desensitization to the 
MCP-1 ligand following prolonged exposure (Volpe et al., 2012). However, it has previously 
been posited that the expression of chemotactic receptors on leukocytes can be modulated by 
external environmental cues in order to fine tune the timing and magnitude of the inflammatory 
response (Burnett, 1992; Fantuzzi et al., 1999). This suggests that the presence of certain ligands 
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within the circulation may precipitate an up- or down-regulation of chemotactic receptors. 
Changes in the expression of the CCR2 receptor and/or the secretion of the MCP-1 ligand may 
therefore have a profound impact on monocyte recruitment, which may ultimately influence 




Resistance exercise is a potent stimulus for acute increases in the concentrations of 
circulating hormones (Smilios et al., 2003). In particular, significant elevations in circulating 
cortisol are observed following resistance exercise of sufficient volume and intensity (Ahtiainen 
et al., 2003). Cortisol accounts for 95% of secreted glucocorticoids in humans, which are 
released from the adrenal cortex in response to the stress of exercise (Kraemer & Ratamess, 
2005). The constitutive expression of glucocorticoid receptors (GCR) on human peripheral blood 
mononuclear cells (PBMCs) (Bartholome et al., 2004), as well as the potential for these receptors 
to up-regulate in response to immunostimulation, has previously been documented (Bartholome 
et al., 2004; Spies et al., 2007). Consequently, the expression of GCR on monocytes provide the 
molecular basis for these cells to be targets of cortisol signaling prior to, during, and following 
resistance exercise.  
Resent research suggests that cortisol’s regulation of innate immunity may be both pro- 
and anti-inflammatory (Sorrells & Sapolsky, 2010; Yeager, Pioli, & Guyre, 2011). Consistent 
with this, glucocorticoids have been shown to modulate the expression of the pro-inflammatory 
receptor CCR2 on human monocytes in vitro (Okutsu et al., 2008; Penton-Rol et al., 1999; 
Pettersson et al., 2005). Penton-Rol et al. (1999) report a selective up-regulation of CCR2 mRNA 
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expression following treatment of human monocytes with the corticosteroid dexamethasone 
(Penton-Rol et al., 1999). In lieu of an increased rate of nuclear transcription, the corticosteroid 
treatment was observed to augment the CCR2 mRNA half-life. This effect was associated with 
increased chemotaxis towards MCP-1, as measured using a chemotaxis micro-chamber in vitro, 
and was abolished in the presence of glucocorticoid receptor agonist RU486. This indicates that 
the up-regulation of CCR2 was mediated by GCR.  
Similar findings have been observed by Okutsu and colleagues (2008). Human PBMC’s 
from untrained men incubated with either serum drawn immediately and 2 hours post-exercise 
(60 minutes cycling at 70% VO2peak) or cortisol alone, exhibit a dose- and time-dependent 
increase in CCR2 expression in vitro. This expression was 2.4 and 1.3 times higher than that of 
the control condition, respectively. Additionally, the up-regulation of CCR2 was achievable with 
the lower limit of physiological plasma cortisol concentration. Similar to the findings of Penton-
Rol and colleagues (1999), the effects of cortisol and serum on CCR2 were abolished in the 
presence of the GCR agonist RU486. Notwithstanding, the exercise stimulus was not sufficient 
to cause an up-regulation of CCR2 in vivo.  
Taken together, examinations of the effects of glucocorticoids on monocyte CCR2 
expression in vitro suggest that cortisol, and other corticosteroids may augment the chemotactic 
capacity of these cells to inflammatory stimuli. Notwithstanding, the up-regulation of CCR2 in 
the presence of glucocorticoids in vitro requires at least 4-6 hours incubation time (Okutsu et al., 
2008; Penton-Rol et al., 1999). Consequently, in vitro observations may not translate to the up-
regulation of CCR2 in vivo. This is consistent with the absence of in vivo changes to CCR2 
expression following cycling activity (Okutsu et al., 2008). The effects of resistance exercise on 





In order for monocytes to successfully migrate into damaged tissue, they must first make 
contact with the endothelium immediately adjacent to it. However, the shear stress associated 
with blood flow in vivo make this contact functionally complex. Therefore, monocyte 
transendothelial migration requires a series of sequential steps. These steps include capture, 
rolling, activation, arrest, adhesion strengthening, and intravascular (intraluminal) crawling, that 
together, ultimately lead to paracellular or transcellular monocyte transmigration (Ley, 
Laudanna, Cybulsky, & Nourshargh, 2007; Schenkel et al., 2004). Each step in the process is a 
fundamental pre-requisite for the next step, in what is known as the leukocyte adhesion cascade. 
The leukocyte adhesion cascade has previously been described in detail by Ley and colleagues 
(2007) and is depicted in Figure 5. Several leukocyte specific structural families of adhesion 
molecules are known to mediate each step within the cascade. However; for the purposes of this 
review, only molecules known to directly mediate intravascular crawling will be discussed. This 
step is the direct pre-requisite to monocyte transmigration.   
Prior to crossing the walls of the post-capillary venules, monocytes are observed to crawl 
inside the blood vessels (intravascular crawling), seeking preferred sites of transmigration (Ley 
et al., 2007). Intravascular crawling is predominantly mediated by cytoskeletally regulated 
heterodimers called integrins (Schenkel et al., 2004; Sumagin, Prizant, Lomakina, Waugh, & 
Sarelius, 2010), which interact with their constitutive or inducible endothelial ligands (Laudanna 
& Alon, 2006). Under homeostatic conditions, integrins are maintained in a low-affinity 
conformational state (Shimaoka et al., 2003). However; in the presence of inflammation, select 
chemokines are secreted, which serve to activate/enhance the affinity and/or surface expression 
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of integrins (Ley et al., 2007). This subsequently increases the ligand binding capacity of the cell 
(Constantin et al., 2000; Montresor, Toffali, Constantin, & Laudanna, 2012; Sun et al., 2014), 
while also facilitating a marked decrease in the rate of ligand dissociation (Ley et al., 2007). 
Cumulatively, these effects lead to the augmentation of endothelial adhesion.  
Integrins exist as two non-covalently bound alpha and beta subunits, which pair to form a 
heterodimer. Each heterodimer consists of a large extracellular domain capable of binding 
proteins in the extracellular environment (Hynes, 2002). The functional specificity of these 
molecules resides largely within the extracellular domain of the molecule (Xiong, Chen, & 
Zhang, 2003; Zen et al., 2011). CD11a and CD11b are alpha glycoprotein chains, which combine 
with the beta chain CD18 to form the extracellular domain of β2 integrin receptors LFA-1 
(Lymphocyte function-associated antigen 1; CD11a/CD18) and CR3 (cell adhesion molecule 
complement receptor 3; Mac-1; CD11b/CD18) (Ehlers, 2000). Both CD11a and CD11b are 
reported to have functional roles in monocyte crawling; however, CD11b mediated crawling is 
reported to predominate during inflammation (Sumagin et al., 2010).  
CD11b is expressed exclusively on granulocytes and monocytes (Dunne, Ballantyne, 
Beaudet, & Ley, 2002). The counter-ligand/receptor for CD11b is recognized as intracellular 
adhesion molecule-1 (ICAM-1) (Diamond et al., 1990), and is upregulated on the surface of 
inflamed endothelial cells following tissue injury (Paulis et al., 2012). Pursuant to damage, the 
intravascular crawling behavior of monocytes is reported to occur in a CD11b/ICAM-1 
dependent manner (Dunne, Collins, Beaudet, Ballantyne, & Ley, 2003; Schenkel et al., 2004). 
Ligation of ICAM-1, especially under conditions of high ICAM-1 expression, is thought to 
trigger cytoplasmic signaling events that lead to the translocation of apical ICAM-1, allowing the 
extension of leukocyte membrane protrusions into endothelial-cell junctions (Schenkel et al., 
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2004). This response is thought to result in the formation of channels through which the 
monocyte can migrate. Consistent with this role, the delivery of a monoclonal antibody directed 
against an epitope of the CD11b molecule in vivo, has been shown to inhibit monocyte 
recruitment to inflammatory stimuli (H. Rosen & Gordon, 1987). Additionally, it has recently 
been shown that suppression of the CD11b molecule in vitro results in a concomitant decrease in 
endothelial adhesion (Arakawa et al., 2010; Mesri et al., 1998). Further, blockade of CD11b in 
conjunction with LFA-1 has been shown to result in impaired cell movement, and the inability of 
monocytes to reach endothelial cell junctions (Schenkel et al., 2004). Consequently, it appears 




Figure 5. The leukocyte adhesion cascade.  
Getting to the site of inflammation: the leukocyte adhesion cascade. Ley et al. (2007). ESAM, 
endothelial cell-selective adhesion molecule; ICAM1, intercellular adhesion molecule 1; JAM, 
junctional adhesion molecule; LFA1, lymphocyte function-associated antigen 1 (also known as 
αLβ2-integrin); MAC1, macrophage antigen 1; MADCAM1, mucosal vascular addressin cell-
adhesion molecule 1; PSGL1, P‑selectin glycoprotein ligand 1; PECAM1, platelet/endothelial-
cell adhesion molecule 1; PI3K, phosphoinositide 3‑kinase; VCAM1, vascular cell-adhesion 
molecule 1; VLA4, very late antigen 4 (also known as α4β1-integrin). Included with permission 
from Nature Publishing Group; License #: 3592000371954.  
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In accordance with these reports, an up-regulation in the expression of the CD11b has 
previously been linked with the increased ability of monocytes to adhere to endothelial cells 
(Weber, Erl, & Weber, 1995). Increases in CD11b expression on monocytes has previously been 
reported following long distance running (Nielsen & Lyberg, 2004), and high-volume resistance 
training (Gonzalez et al., 2014; Jajtner et al., 2014). This up-regulation has previously been 
associated with increased circulating MCP-1 (K. Takahashi et al., 2003; Vaddi & Newton, 1994) 
and TNFα (Gamble et al., 1985; Montecucco et al., 2008). MCP-1 and/or TNFα mediated up-
regulation of CD11b expression may augment the ability of monocytes to adhere to the 
endothelium in areas of damage, which could ultimately lead to a higher rate of infiltration, and 




Together, murine and human in vivo, as well as in vitro examinations of 
monocyte/macrophage responses to tissue damage/inflammation, have shed considerable light on 
the integrative function of distinct immune cells in the resolution of tissue inflammation. 
Following tissue injury, there is a predictable series of responses by innate immune system. 
While the duration and intensity of certain events may change, the systematic activation and 
redistribution of leukocyte subsets in response to injury is fairly consistent. Pursuant to a 
disturbance in tissue homeostasis, patrolling non-classical monocytes and resident macrophages 
are among the first cells to respond. These cells are able to sense the disturbance in homeostasis, 
and respond by rapidly producing cytokines and chemokines, which subsequently leads the 
activation and expression of specific receptors on endothelial cells and leukocytes. These 
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receptors may also be responsive to endocrine signals. Neutrophils are the first cell to invade the 
site of injury, where they release granule contents that modify the damaged tissue and promote 
the extravasation of classical inflammatory monocytes. The life-span of emigrated neutrophils is 
rather short and is subject to modification by pro- or anti-apoptotic signals, some of which are 
produced by macrophages. Macrophages and apoptotic neutrophil signals prevent further 
infiltration of neutrophils, but continue to signal classical monocytes and promote their influx. 
Classical monocytes subsequently enter the tissue and differentiate into M1 pro-inflammatory 
macrophages, which function to phagocytize opsonized cellular debris and apoptotic neutrophils 
while stimulating MPC proliferation. The eventual clearance of apoptotic neutrophils and 
cellular debris promotes a shift in macrophage phenotype from a pro-inflammatory M1 to an 
anti-inflammatory M2 phenotype, which leads to the release of specific growth factors that 
ultimately modulate to the reconstitution of tissue homeostasis. The sequential activation and 






Figure 6. Phagocyte interactions in inflammation.  
Phagocyte Partnership during the Onset and Resolution of Inflammation. Soehnlein & Lindbom 
(2010). IG-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte–monocyte 
colony-stimulating factor; IL, interleukin; PGE2, prostaglandin E2; TGFβ, transforming growth 
factor-β;TNF, tumor necrosis factor. Included with permission from Nature Publishing Group; 
License #: 3582600880056.  
 
It is currently unclear whether the acute inflammatory response differs between various 
resistance exercise protocols. However, given that cortisol has been shown to have the ability to 
modulate monocyte receptor expression in vitro, and the systemic profile of cortisol is known to 
be significantly different between high-intensity and high-volume resistance exercise protocols, 
it is feasible to suggest that systemic immune response may differ between these exercise 
protocols. An increase in monocyte chemotaxis and adhesion increase the likelihood of 
monocyte extravasation, which may subsequently contribute to an augmented macrophage pool 
within the muscle. Since macrophages directly support both the clearance of cellular debris, and 
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the growth of new muscle, training paradigms that maximize the potential for monocyte 





























Ten resistance-trained men (90.1 ± 11.3 kg; 176.0 ± 4.9 cm; 24.7 ± 3.4 yrs; 14.1 ± 6.1% 
body fat) were recruited to participate in this randomized, cross-over design research study.  
Strict recruitment criteria were implemented to increase homogeneity of the sample.  Inclusion 
criteria required participants to be between the ages of 18 and 35 years, with a minimum of one 
year of resistance training experience, and the ability to squat a weight equivalent to their body 
mass.  Participants had 6.7 ± 4.6 years of resistance training experience with an average 
maximum barbell back squat of 172.7 ± 25.2 kg.  All participants were free of any physical 
limitations that may have affected performance.  Additionally, all participants were free of any 
medications and performance enhancing drugs, as determined by a health and activity 
questionnaire.  Following an explanation of all procedures, risks, and benefits, each participant 
provided his informed consent prior to participation in this study.  The research protocol was 
approved by the New England Institutional Review Board prior to participant enrollment.   
 
Maximal Strength Testing 
 
Prior to experimental trials, participants reported to the Human Performance Laboratory 
(HPL) to establish maximal strength (1RM) on all lifts involved in the exercise protocol.  
Participants performed a standardized warm-up consisting of five minutes on a cycle ergometer 
against a light resistance, 10 body weight squats, 10 body weight walking lunges, 10 dynamic 
walking hamstring stretches, and 10 dynamic walking quadriceps stretches.  Following the 
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warm-up, 1RM testing for the barbell back squat and leg press were performed using methods 
previously described (Hoffman, 2006).  Briefly, each participant performed two warm-up sets 
using a resistance of approximately 40-60% and 60-80% of his perceived maximum, 
respectively.  For each exercise, 3-4 subsequent trials were performed to determine the 1RM.  A 
3-5 minute rest period was provided between each trial.  Maximum strength testing was 
administered by the same Certified Strength and Conditioning Specialist to ensure that each 
participant reached the parallel position for each repetition of the squat and that the exercise 
technique was consistent between sessions. For all other exercises, the 1RM was assessed using a 
prediction formula based on the number of repetitions performed to fatigue using a given weight 
(Brzycki, 1993).  Trials not meeting the range of motion criteria for each exercise or where 




On the morning of each trial, participants reported to the HPL after a 10-hour overnight 
fast and having refrained from all forms of moderate to vigorous exercise for the previous 72 
hours. Experimental trials were performed in a balanced, randomized order, and each 
experimental trial was separated by a minimum of one week to ensure adequate recovery.  Each 
participant performed experimental trials at the same time of day to avoid the influence of 
diurnal variations. During each experimental trial, participants performed the standardized warm-
up routine as described above, followed by a lower-body resistance exercise protocol.  Table 1 
depicts the volume (VOL) and heavy (HVY) resistance exercise protocols.  The VOL protocol 
required participants to perform 10 – 12 repetitions with a load of equating to 70% of their 1RM, 
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with a 1-minute rest period between each set and exercise.  The HVY protocol required 
participants to perform 3 – 5 repetitions with a load equating to 90% of their 1RM with a 3-
minute rest period between each set and exercise.  Both protocols included six sets of barbell 
back squats and four sets of bilateral leg press, bilateral hamstring curls, bilateral leg extensions, 
and seated calf raises.  During each protocol, participants were verbally encouraged to complete 
all repetitions for each set.  If the participant was unable to complete the desired number of 
repetitions, spotters provided assistance until the participant completed the remaining repetitions.  
Subsequently, the load for the next set was adjusted so that participants were able to perform the 
specific number of repetitions for each set. 
 
Table 1. Resistance Exercise Protocols 
 
 
Following each resistance exercise protocol, participants remained in the laboratory for 
all post-exercise assessments.  Blood samples were obtained at six time points over the course of 
the study: baseline (BL), immediately post-exercise (IP), 30 minutes post-exercise (30P), 1 hour 
post-exercise (1H), 2 hours post-exercise (2H), and 5 hours post-exercise (5H) 
To control for diet, participants were provided a standardized low protein, low 
carbohydrate breakfast (7 grams protein; 3 grams carbohydrate; 13 grams fat) following BL 
assessments.  Immediately following IP blood sampling, participants were also provided a 
flavored drink (355 mL, 0 grams protein, 2.5 grams carbohydrates, 0 gram fat).  Participants 
Exercise Order Sets x Repetitions Intensity Rest Interval Sets x Repetitions Intensity Rest Interval
1. Barbell Back Squats 6 x 10-12 6 x 3-5
2. Bilateral Leg Press 4 x 10-12 4 x 3-5
3. Bilateral Hamstring Curls 4 x 10-12 4 x 3-5
4. Bilateral Leg Extensions 4 x 10-12 4 x 3-5
5. Seated Calf Raise 4 x 10-12 4 x 3-5
70% 1-RM 1 Minute 90% 1-RM 3 Minutes
Volume Protocol (VOL) Heavy Protocol (HVY)
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were permitted to drink water ad libitum during experimental trials, and water consumption was 
monitored.   
Dietary Logs 
 
Participants were instructed to maintain their normal dietary intake leading up to 
experiment trials.  Participants were then instructed to record as accurately as possible everything 
they consumed during the 24 hours prior to the first experimental trial.  For the following 
experimental trial, participants were required to duplicate the content, quantity, and timing of 
their daily diet during the 24 hours prior.  Participants were instructed not to eat or drink (except 




During each experimental trial, blood samples were obtained using a Teflon cannula 
placed in a superficial forearm vein using a three-way stopcock with a male luer lock adapter and 
plastic syringe.  The cannula was maintained patent using an isotonic saline solution (Becton 
Dickinson, Franklin Lakes, NJ, USA).  BL blood samples were obtained following a 15-minute 
equilibration period.  IP blood samples were taken within one minute of exercise cessation.  
Participants were instructed to lie in a supine position for 15 minutes prior to 30P, 1H, 2H, and 
5H blood draws. 
All blood samples were collected into three 6 ml Vacutainer® tubes.  Blood samples 
were drawn into either plain, sodium heparin, or K2EDTA treated tubes.  A small aliquot of 
whole blood was removed and used for determination of hematocrit and hemoglobin 
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concentrations.  The blood in the plain tube was allowed to clot at room temperature for 30 
minutes and subsequently centrifuged at 3,000g for 15 minutes along with the remaining whole 
blood from the other tubes.  The resulting serum and plasma was placed into separate micro-




Blood lactate concentrations were analyzed from plasma using an automated analyzer 
(Analox GM7 enzymatic metabolite analyzer, Analox instruments USA, Lunenburg, MA, USA).  
Hematocrit concentrations were analyzed from whole blood via microcentrifugation (CritSpin, 
Westwood, MA, USA) and microcapillary technique.  Hemoglobin concentrations were analyzed 
from whole blood using an automated analyzer (HemoCue, Cypress, CA, USA).  Plasma volume 
shifts were calculated using the formula established by Dill & Costill (1974).  To eliminate inter-
assay variance, all samples were analyzed in duplicate by a single technician.  Coefficient of 
variation for each assay was 1.4% for blood lactate; 0.4% for hematocrit; and 0.6% for 
hemoglobin.   
  Circulating concentrations of testosterone and cortisol were assessed via enzyme-linked 
immunosorbent assays (ELISA) and a spectrophotometer (BioTek Eon, Winooski, VT, USA) 
using commercially available kits.  Myoglobin concentrations were determined via ELISA 
(Calbiotech, Spring Valley, CA, USA) and a spectrophotometer.  Lactate dehydrogenase (LDH) 
concentrations were determined via kinetic ELISA (Sigma-Aldrich, St. Louis, MO, USA) and a 
spectrophotometer.  To eliminate inter-assay variance, all samples for each assay were thawed 
once and analyzed in duplicate in the same assay run by a single technician.  Coefficients of 
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variation for each assay were 4.8% for testosterone; 5.3% for cortisol; 4.1% for myoglobin; and 
4.8% for LDH.  
Plasma samples were assayed for concentrations of monocyte chemoattractant protein 1 
(MCP-1) and tumor necrosis factor-alpha (TNF-α), using a multiplex cytokine assay (Milliplex, 
Cat no. HCYTOMAG-60K; Millipore, Billerica, MA) on a MAGPIX instrument (Luminex, 
Austin, TX), according to the manufacturer's instructions. All samples were run in duplicate with 




Cell staining was performed as described previously (Gonzalez et al., 2014; Jajtner et al., 
2014; Townsend et al., 2013). Analysis of target receptor expression on CD14++CD16- cells was 
completed at BL, IP, 1H, 2H and 5H time points. K2EDTA-treated peripheral whole blood was 
used to identify monocytes, and quantify target receptor expression by direct 
immunofluorescence and flow cytometry (BD Biosciences, San Jose, CA). Erythrocytes were 
first lysed from 350 μl of K2EDTA-treated whole blood with BD Pharm Lyse solution (BD 
Biosciences, San Jose, CA) within 30 min of collection. Samples were then washed in staining 
buffer containing 1 x phosphate-buffered saline (PBS) and fetal bovine serum (FBS) (BD 
Pharmingen Stain Buffer; BD Biosciences) followed by centrifugation and aspiration for a total 
of three washes. Leukocytes were then resuspended in 100 μl BD Pharmingen stain buffer (BD 
Biosciences). Direct staining methods were used to label CD14 and CD16 (monocyte 
identifiers), CCR2 (monocyte chemotaxis), CD120a (receptor for TNFα), CD11b (monocyte 
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adhesion), and glucocorticoid receptor (GCR). Due to the number of receptors of interest, two 
separate cell preparations were performed.  
For preparation 1, Alexa Fluor® 488 conjugated anti-CD120a (FAB225G, IgG; R&D 
Systems), allophycocyanin (APC) conjugated anti-CD11b (550019; IgG1; BD Pharmingen™), 
PerCP Cy5.5 conjugated anti-CD14 (562692; IgG2b; BD Pharmingen™) and PE conjugated anti-
CD16 (561313; IgG1; BD Pharmingen™) were used in the receptor labeling process. Surface 
staining for preparation 1 was performed by adding 5µL of directly conjugated Alexa Fluor® 
488-anti-CD120a, 20µL of directly conjugated APC-anti-CD11b, 5 𝜇𝜇L of directly conjugated 
PerCP Cy5.5-anti-CD14, and 5 𝜇𝜇L of directly conjugated PE-anti-CD16 to the cell suspension, 
followed by incubation in the dark for 30 minutes at room temperature. Cells were then 
resuspended in 1.0mL of stain buffer for immediate flow cytometry analysis. 
For preparation 2, PerCP Cy5.5 conjugated anti-CD14 (562692; IgG2b; BD Pharminigen), 
allophycocyanin (APC) conjugated anti-CCR2 (FAB151A; IgG2b; R&D Systems), and 
DyLight® 488 conjugated anti-GR (ab139892; IgG; Abcam), were used in the receptor labeling 
process. Surface staining for preparation 2 was performed by adding 5 𝜇𝜇L of directly conjugated 
PerCP Cy5.5-anti-CD14, and 10 µL of directly conjugated APC-anti-CCR2 to the cell 
suspension followed by incubation in the dark for 30 minutes at room temperature. Cells were 
then washed in staining buffer followed by centrifugation and aspiration. Cells were 
subsequently resuspended in 250 𝜇𝜇L of fixation and permeabilization solution (BD 
cytofix/cytoperm™, BD Biosciences, San Jose, CA), and set to incubate for 20 minutes in the 
dark at 4° C. Following incubation, cells were washed in 1mL of Perm Wash Buffer (BD 
Perm/Wash™, BD Biosciences, San Jose, CA), followed by centrifugation and aspiration, and 
the addition of 50 𝜇𝜇L of Perm Wash Buffer. Intracellular staining for preparation 2 was 
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accomplished by adding 1 𝜇𝜇L of directly conjugated DyLight® 488-anti-GR to the cell 
suspension followed by incubation in the dark for 30 minutes at 4° C. Cells were then washed in 
1.0mL of Perm Wash Buffer and resuspended in 1.0mL of stain buffer for flow cytometry 




Flow cytometry analysis of stained cells was performed on a BD Accuri C6 flow 
cytometer (BD Biosciences), equipped with BD Accuri analysis software (BD Biosciences). 
Forward- and side-scatter, along with four fluorescent channels of data, were collected using two 
lasers, providing excitation at 488 nm and 640 nm. A minimum of 10,000 events, defined as 
CD14+ monocytes, were obtained with each sample. Monocytes were determined as CD14+ 
events. Compensation for fluorescence spillover was achieved through single staining of anti-
mouse Ig, κ/negative control compensation particles (BD CompBeads, BD Biosciences). 
Unstained leukocytes from human peripheral blood taken at baseline was used as a negative 
control for CD14, CD16, CD120a, CD11b, and CCR2 expression, while an IgG isotype control 




The gating protocol for preparation 1 is depicted in Figure 3. Viable cells were obtained 
using forward-scatter height (FSC-H) x forward-scatter area (FSC-A) gating to eliminate debris, 
necrotic cells and artifact (Figure 3: Panels 1 and 2). Following this, monocytes sub-populations 
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were determined via 2-dimensional histogram (quadrant analysis) based upon CD14 and CD16 
expression (Tallone et al., 2011). The quadrant gate was set relative to the unstained control 
sample (Figure 3: Panel 3). Analysis of target receptor expression was completed on classical 
CD14+CD16- monocytes (Figure 3: Panel 4; lower right quadrant) using one dimensional 
histograms. An unstained control sample was used to set the gate for all target receptors (Figure 
3: Panel 5). The mean fluorescence intensity for each target receptor on CD14+CD16- monocytes, 
which represents the mean density of each receptor per cell, was quantified by overlaying the 
histogram plots of target receptors to the control samples (Figure 3: Panel 6).   
 
 
Figure 7. Gating Protocol for Preparation 1 
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The gating protocol for preparation 2 is depicted in Figure 4. Viable cells were obtained 
using forward-scatter height (FSC-H) x forward-scatter area (FSC-A) gating to eliminate debris, 
necrotic cells and artifact (Figure 4: Panels 1 and 2). Monocytes were determined via one-
dimensional histogram analysis of CD14+ cells relative to unstained control (Figure 4: Panels 3 
and 4). CCR2 expression on CD14+ monocytes was also quantified via one-dimensional 
histogram analysis relative to unstained control (Figure 4: Panels 5 and 6). Analysis of 
glucocorticoid receptor expression was assessed on CD14+/CCR2+ cells (corresponding to 
classical monocytes) relative to IgG isotype control (Figure 4: Panels 7 and 8). The mean 
fluorescence intensity for each target receptor was quantified by overlaying the histogram plots 
to their respective control samples. 
 
 






Biochemical and receptor expression changes were analyzed using a two factor (time x 
trial) repeated measures analysis of variance (ANOVA). In the event of a significant F ratio, 
dependent t-tests were used for pairwise comparisons between trials. Follow-up one way 
repeated measures ANOVA were used to determine time effects for each treatment. In the event 
of a significant F ratio, least significant difference (LSD) post-hoc tests were used for pairwise 
comparisons across time. Comparisons between trials were further analyzed using Cohen’s d. 
Consistent with others (Clemson et al., 2012), interpretations of Cohen’s d were evaluated in 
accordance with Thalheimer and Cook (2002) at the following levels: negligible effect (≥ −.15 
and < .15), small effect (≥ = .15 and < .40), medium/moderate effect (≥ = .40 and < .75), large 
effect (≥ = .75 and <1.10), very large effect (≥ = 1.10 and <1.45), and huge effect ≥ 1.45). Time 
effects were further analyzed using partial eta squared (η2p). Interpretations of η2p were evaluated 
in accordance with Cohen (1988) at the following levels: small effect (0.01-0.058), medium 
effect (0.059-0.137) and large effect (> 0.138). The net area under the curve (AUC) was also 
calculated for biochemical measures and receptor expression using a standard trapezoidal 
technique. AUC analyses were performed across either IP, 30P, 1H, 2H and 5H time points 
(biochemical measures), or IP, 1H, 2H and 5H time points (receptor expression), and were 
assessed using paired samples t-tests. AUC was used as a proxy to for total receptor expression 
over time. Pearson’s product-moment correlations were used to examine the association between 
circulating hormones, cytokines and cellular receptor expression on CD14++CD16- monocytes. 
Absolute values of r were interpreted according to the recommendations of Evans (1996), at the 
following levels: very weak correlation (.00 to .19), weak correlation (.20 to .39), moderate 
correlation (.40 to .59), strong correlation (.60 to .79), and very strong correlation (.80 to 1.0). 
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Correlations between the AUC of circulating measures and the AUC of receptor expression were 
assessed at IP, 1H, 2H and 5H time points for consistency. Prior to statistical procedures, all data 
was assessed for sphericity. If the assumption of sphericity was violated, a Greenhouse-Geisser 
correction was applied. Significance was accepted at an alpha level of p ≤ 0.05 and all data are 






















CHAPTER IV: FINDINGS 
 
Resistance Exercise Protocol 
 
 Differences in workout volume between trials are presented in Figure 9. Workout volume 
(sets x load x reps) was significantly greater for VOL (45300.0 ± 13919.8 kg) compared to HVY 
(33633.5 ± 5661.9 kg) (+35%; d = 1.16; p = 0.005).  
 
 
Figure 9. Workout Volume.  
Groups: HVY = Heavy; VOL = Volume. * = Significantly greater volume (p ≤ 0.05); Data 










 Changes in plasma lactate concentrations are depicted in Table 2. A significant 
interaction between trials was observed for plasma lactate concentrations (F = 41.7; p = < 0.001; 
η2p = 0.82). Plasma lactate was significantly greater during VOL at IP (+106%; d = 2.82; p = < 
0.001), 30P (+105%; d = 2.10; p = < 0.001) and 1H (+71%; d = 1.77; p = < 0.001) compared to 
HVY. Significant time effects were observed for both HVY (F = 31.8; η2p = 0.78; p = < 0.001) 
and VOL (F = 133.4; η2p = 0.94; p = < 0.001). During HVY, lactate was significantly elevated at 
IP (+396%; d = 3.1; p = < 0.001), 30P (+176%; d = 1.82; p = 0.004), 1H (+87%; d = 1.59; p = 
0.010) and 5H (+95%; d = 1.55; p = 0.007). During VOL, lactate was significantly elevated at IP 
(+818%; d = 6.56; p = 0.001), 30P (+409%; d = 4.48; p = < 0.001), 1H (+187%; d = 3.75; p = < 
0.001), 2H (+73%; d = 1.32; p = 0.002) and 5H (+93%; d = 1.36; p = 0.009). AUC was 
significantly greater for VOL compared to HVY (+51%; d = 1.28; p = 0.009).  
 




BL IP 30P 1H 2H 5H 
HVY 1.24 ± 0.21 6.12 ± 2.34 ‡ 3.41 ± 1.77 ‡ 2.31 ± 0.99 ‡ 1.81 ± 1.00 2.41 ± 1.11 ‡ 
VOL 1.38 ± 0.37 12.63 ± 2.53 ‡* 7.01 ± 1.83 ‡* 3.94 ± 0.95 ‡* 2.39 ± 1.08 ‡ 2.66 ± 1.36 ‡ 
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 
30P = 30 minutes post; 1H = One hour post; 2H = Two hours post; 5H = Five hours post. * = 
Significant difference between trials; ‡ = Significant increase relative to BL (p ≤ 0.05); Data 






 Changes in circulating myoglobin concentrations are presented in Figure 10. A 
significant interaction between trials was observed for circulating myoglobin (F = 8.3; η2p = 
0.48; p = 0.003). Myoglobin was significantly greater during HVY at IP (+79%; d = 1.11; p = 
0.022), and 30P (+92%; d = 1.28; p = 0.009) compared to VOL. A trend towards HVY being 
greater than VOL at 1H was observed (+41%; d = 0.74; p = 0.054). Significant time effects were 
observed for both HVY (F = 21.5; η2p = 0.71; p = < 0.001) and VOL (F = 26.3; η2p = 0.75; p = < 
0.001). During HVY, myoglobin was significantly elevated at IP (+461%; d = 2.14; p = 0.001), 
30P (+588%; d = 2.40; p = 0.001), 1H (+582%; d = 2.43; p = 0.001), 2H (+445%; d = 2.30; p = 
0.001), and 5H (+285%; d = 2.32; p = 0.001). During VOL, myoglobin was significantly 
elevated IP (+162%; d = 2.89; p = < 0.001), 30P (+200%; d = 2.81; p = < 0.001), 1H (+305%; d 
= 3.02; p = < 0.001), 2H (+303%; d = 2.86; p = < 0.001), and 5H (+ 164%; d = 2.47; p = 
0.001). Myoglobin AUC is presented in Figure 11. AUC analysis revealed no significant 






Figure 10. Myoglobin concentration following resistance exercise.  
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 
30P = 30 minutes post; 1H = One hour post; 2H = Two hours post; 5H = Five hours post. * = 
Significant difference between trials; ‡ = Significant increase relative to BL (p ≤ 0.05); Data 




Figure 11. Myoglobin area under the curve (AUC).  






 Changes in circulating LDH concentrations are presented in Figure 12. No significant 
interactions were noted between trials for circulating LDH (F = 1.3; η2p = 0.16; p = 0.283). 
However, a significant main effect was observed (F = 10.2; η2p = 0.59; p = < .001). When 
collapsed across groups, LDH was significantly elevated above baseline at IP (+34%; d = 1.13; p 
= 0.006), 30P (+22%; d = 0.78; p = 0.004), 1H (+24%; d = 0.92; p = 0.004), 2H (+33%; d = 
1.17; p = 0.001) and 5H (+1.47; d = 1.47; p = <0.001). LDH AUC is presented in Figure 13. 




Figure 12. Lactate dehydrogenase (LDH) concentration following resistance exercise.  
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 
30P = 30 minutes post; 1H = One hour post; 2H = Two hours post; 5H = Five hours post. ‡ = 






Figure 13. Lactate dehydrogenase (LDH) area under the curve (AUC).  
Groups: HVY = Heavy; VOL = Volume. * = Significantly greater AUC (p ≤ 0.05); Data reported 





 Changes in circulating TNFα concentrations are presented in Figure 20. No significant 
interactions were noted between trials for circulating TNFα (F = 1.7; η2p = 0.16; p = 0.218). 
However, a significant main effect was observed (F = 12.7; η2p = 0.56; p = < 0.003). When 
collapsed across groups, TNFα was significantly elevated at IP (+53%; d = 1.65; p = 0.001), 30P 
(+66%; d = 1.60; p = 0.002), 1H (+66%; d = 1.56; p = 0.002) and 2H (+33%; d = 1.18; p = 
0.004). TNFα AUC is presented in Figure 21. AUC analysis revealed no significant differences 






Figure 14. Tumor Necrosis Factor - alpha (TNFα) concentration following resistance exercise. 
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 
30P = 30 minutes post; 1H = One hour post; 2H = Two hours post; 5H = Five hours post. ‡ = 




Figure 15. Tumor Necrosis Factor - alpha (TNFα) area under the curve (AUC).  





Changes in circulating MCP-1 concentrations are presented in Figure 18. No significant 
interactions were observed between trials for circulating MCP-1, although a trend was noted (F = 
2.2; η2p = 0.19; p = 0.074). However, a significant main effect was observed (F = 6.4; η2p = 0.42; 
p = < 0.001). When collapsed across groups, MCP-1 was significantly elevated at IP (+76%; d = 
1.56; p = 0.005), 30P (+110%; d = 2.02; p = 0.002), 1H (+110%; d = 1.77; p = 0.003), 2H 
(+43%; d = 1.21; p = 0.006) and 5H (+37%; d = 0.90; p = 0.033). MCP-1 AUC is presented in 




Figure 16. Monocyte chemoattractant protein-1 (MCP-1) concentration following resistance 
exercise.  
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 
30P = 30 minutes post; 1H = One hour post; 2H = Two hours post; 5H = Five hours post. ‡ = 






Figure 17. Monocyte Chemoattractant Protein - 1 (MCP-1) area under the curve (AUC).  





Changes in circulating cortisol concentrations are presented in Figure 16. A significant 
interaction between trials was observed for cortisol (F = 10.7; η2p = 0.54; p = < 0.001). Cortisol 
was significantly greater during VOL at IP (+57%; d = 1.08; p = 0.012), 30P (+113%, d = 2.12; 
p = < 0.001), 1H (+91%; d = 2.00; p = 0.003) and 2H (+57%; d = 1.19p; p = 0.018), compared 
to HVY. Significant time effects were also observed for both HVY (F = 8.9; η2p = 0.50; p = < 
0.001) and VOL (F = 23.5; η2p = 0.72; p = < 0.001). During HVY, cortisol was significantly 
decreased at 2H (-30%; d = 0.91; p = 0.028) and 5H (-53%; d = 1.87; p = < 0.001) compared to 
BL. During VOL, cortisol was significantly elevated at IP (+95%; d = 1.40; p = 0.001), 30P 
(+112%; d = 1.87; p = 0.001), and 1H (+81%; d = 1.51; p = 0.004) compared to BL, and was 
significantly lower than BL at 5H (-48%; d = 1.07; p = <0.001). Cortisol AUC is presented in 
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Figure 18. Cortisol concentration following resistance exercise.  
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 
30P = 30 minutes post; 1H = One hour post; 2H = Two hours post; 5H = Five hours post. * = 
Significant difference between trials; ‡ = Significant increase relative to BL (p ≤ 0.05); § = 





Figure 19. Cortisol area under the curve (AUC).  
Groups: HVY = Heavy; VOL = Volume. * = Significantly greater AUC (p ≤ 0.05); Data reported 





Changes in circulating testosterone concentrations are presented in Figure 14. A trend 
was observed between trials for circulating testosterone (F = 2.8; η2p = 0.24; p = 0.080). 
Additionally, a trend towards a main effect was observed for circulating testosterone (F = 3.5; η2p 
= 0.28; p = 0.075). However, neither reached significance. Testosterone AUC is presented in 






Figure 20. Testosterone concentration following resistance exercise.  
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 
30P = 30 minutes post; 1H = One hour post; 2H = Two hours post; 5H = Five hours post. Data 





Figure 21. Testosterone area under the curve (AUC).  




Plasma Volume Shifts 
 
Relative to BL, plasma volume shifts were significantly different between trials at IP (p = 
0.016).  The difference between trials was not significant for any other time-point. During VOL, 
plasma volume decreased at IP, -8.0 ± 7.7; increased at 30P, 2.1 ± 9.4; increased at 1H, 7.2 ± 
14.0; increased at 2H, 3.7 ± 5.0; and decreased at 5H, -1.6 ± 5.5.  During HVY, plasma volume 
decreased at IP, -1.6 ± 3.1; increased at 30P, 3.3 ± 3.6; increased at 1H, 4.0 ± 3.0; increased at 
2H, 7.2 ± 7.3; and decreased at 5H, -2.6 ± 4.0.  Blood variables were not corrected for plasma 




TNFα Receptor 1 Expression 
 
Changes in TNFr1 expression are presented in Figure 24. No significant interactions were 
observed between trials for TNFαR1 expression on CD14++CD16- monocytes (F = 1.0; η2p = 
0.10; p = 0.443). In addition, no significant main effect for time was observed (F = 1.2; η2p = 
0.12; p = 0.318). TNFr1 AUC is presented in Figure 25. AUC analysis revealed no significant 






Figure 22. Tumor Necrosis Factor Receptor-1 (TNFr1) expression following resistance exercise. 
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 1H 





Figure 23. Tumor Necrosis Factor Receptor-1 (TNFr1) area under the curve (AUC).  
Groups: HVY = Heavy; VOL = Volume. Data reported as means ± SD.  
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CC Chemokine Receptor 2 (CCR2) Expression 
 
 Changes in CCR2 expression are presented in Figure 22. No significant interactions were 
observed between trials for CCR2 expression on CD14++CD16- monocytes (F = 0.4; p = 0.696; 
η2 = 0.04). However, a significant main effect was observed (F = 4.6; p = 0.005; η2 = 0.37). 
When collapsed across groups, CCR2 expression on CD14++CD16- monocytes was significantly 
lower at IP (-25%; d = 1.32; p = 0.033), 1H (-25%; d = 1.37; p = 0.020), 2H (-28%; d = 1.32; p 
= 0.040) and 5H (-29%; 1.43; p = 0.024). CCR2 AUC is presented in Figure 23. AUC analysis 




Figure 24. C-C Chemokine Receptor 2 expression following resistance exercise.  
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 
1H = One hour post; 2H = Two hours post; 5H = Five hours post. § = Significant decrease 






Figure 25. C-C Chemokine Receptor 2 area under the curve (AUC).  
Groups: HVY = Heavy; VOL = Volume. Data reported as means ± SD.  
 
 
Glucocorticoid Receptor Expression 
 
 Changes in GCR expression are presented in Figure 28. No significant 
interactions were noted between trials for Glucocorticoid receptor expression on CD14++CD16- 
monocytes (F = 0.9; p = 0.460; η2p = 0.12). A significant time effect was observed (F = 4.0; p = 
0.011; η2p = 0.36). However; when collapsed across groups, no significant elevations above 
baseline were observed (p = > 0.131). GCR AUC is presented in Figure 29. AUC analysis 






Figure 26. Glucocorticoid receptor expression following resistance exercise.  
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 





Figure 27. Glucocorticoid receptor area under the curve (AUC).  




CD11b Receptor Expression 
 
 Changes in CD11b receptor expression are presented in Figure 26. No significant 
interactions were observed between trials for CD11b expression on CD14++CD16- monocytes (F 
= 0.7; p = 0.599; η2p = 0.07). However, a significant time effect was observed (F = 6.0; p = 
0.001; η2p = 0.40). When collapsed across groups, CD11b receptor expression on CD14++CD16- 
monocytes was significantly greater at 1H (+28%; d = 0.71; p = 0.001). A trend towards an 
increase in CD11b receptor expression was observed at IP (+21%; d = 0.55; p = 0.067). 
Additionally, a trend towards a decrease in CD11b receptor expression was observed at 5H (-
17%; d = 0.50; p = 0.082). CD11b AUC is presented in Figure 27. AUC analysis revealed no 




Figure 28. CD11b expression following resistance exercise.  
Groups: HVY = Heavy; VOL = Volume.  Time points: BL = Baseline; IP = Immediately-post; 
1H = One hour post; 2H = Two hours post; 5H = Five hours post. ‡ = Significant increase 




Figure 29. CD11b area under the curve (AUC).  





CD11b receptor expression was positively correlated with circulating MCP-1 at 1H (r = 










CHAPTER V: DISCUSSION 
 
The findings of this study indicate that changes in CCR2, CD11b, and GCR expression 
on CD14++CD16- monocytes are similar following acute bouts of high-intensity, and high-
volume resistance exercise. When collapsed across groups, CCR2 expression was significantly 
lower at IP, 1H, 2H and 5H post-exercise, while CD11b expression was significantly elevated at 
1H post-exercise only. GCR expression was not significantly different from baseline at any time 
point. Plasma concentrations of myoglobin were significantly higher following HVY compared 
to VOL; however, both protocols resulted in significant elevations above BL at all post-exercise 
time points. No difference between trials was observed for LDH, however AUC was 
significantly greater in HVY compared to VOL. Changes in plasma TNFα, and MCP-1 
concentrations were similar between HVY and VOL. As expected, significant elevations in 
plasma cortisol concentrations were observed following VOL only, although this did not appear 
to be related to changes in receptor expression. Plasma testosterone concentrations and TNFr1 
receptor expression did not appear to be affected by resistance exercise. 
The propagation of muscle damage results in an inflammatory response that is 
characterized by the production of pro-inflammatory cytokines such as TNFα. Our results 
indicate that plasma TNFα is rapidly increased following resistance exercise. Relative to BL, 
plasma TNFα was significantly increased at IP, 30P, 1H and 2H post-exercise, and this was 
similar between HVY and VOL. This suggests that resistance exercise, irrespective of HVY or 
VOL, resulted in a robust post-exercise inflammatory response. This is consistent with prior 
work from our laboratory (Townsend et al., 2015). We have previously reported significant 
increases in plasma TNFα immediately, and 30 minutes post-exercise, following an acute bout of 
high-volume resistance exercise in well-trained males. In the present study, we further 
68 
 
characterize the TNFα response to damaging resistance exercise, demonstrating that plasma 
concentrations remain elevated for up to 2 hours post-exercise. In contrast to our findings, a 
number of studies report no changes in plasma TNFα following exercise. Brenner et al. (1999) 
found no changes in plasma TNFα concentrations following an acute bout of high-volume lower-
body resistance exercise in untrained males (Brenner et al., 1999). Similarly, Smith et al. (2000) 
found no changes in plasma TNFα following high-volume eccentric resistance exercise at 100% 
1RM in untrained males. Further, Peake et al. (2006) found no changes in plasma TNFα 
concentrations following submaximal and maximal lengthening contractions of the elbow flexors 
in untrained males (Peake, Nosaka, Muthalib, & Suzuki, 2006). Differences between the present 
study and these other investigations suggest that the cytokine response may differ between 
trained and untrained individuals. There is evidence to suggest that the leukocyte and cytokine 
response may be delayed following significant tissue damage (Paulsen et al., 2005; Suzuki et al., 
2002). In untrained individuals, an exercise stimulus of sufficient magnitude, particularly if 
unaccustomed, may result in a more pronounced muscle damage compared to trained 
individuals. This may subsequently lead to a delayed cytokine response, which may explain 
some of the differences between studies. Notwithstanding, the temporal behavior of cytokines in 
response to resistance exercise requires further investigation.  
TNFα plays several important roles in inflammation, including inducing the secretion of 
MCP-1 (Murao et al., 2000), up-regulating ICAM-1 and P-selectin adhesion molecules on 
endothelial cells (Bernot, Peiretti, Canault, Juhan-Vague, & Nalbone, 2005), and up-regulating 
CD11b expression on both neutrophils and monocytes (Montecucco et al., 2008; Sumagin et al., 
2010). These effects are mediated via binding with its cognate membrane receptors TNFr1 
(CD120a) and TNFr2 (CD120b) (Hijdra, Vorselaars, Grutters, Claessen, & Rijkers, 2012). 
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However, TNFr1 appears to be the key mediator of TNFα signaling (Grell, Wajant, 
Zimmermann, & Scheurich, 1998; Wajant, Pfizenmaier, & Scheurich, 2003). TNFr1 expression 
did not change significantly in response to HVY or VOL resistance exercise. We have previously 
reported a significant increase in TNFr1 receptor expression on monocytes following acute bouts 
of high-volume resistance exercise in well-trained males (Townsend et al., 2013; Townsend et 
al., 2015). However, in contrast to the present study, this observation was made on CD14++ 
monocytes, without further differentiation based on the expression of CD16 antigen. Classical 
and intermediate monocytes both express a high level of CD14 antigen (Wong et al., 2011), 
which prevents their differentiation in the absence of a secondary antibody. Recent research 
suggests that intermediate monocytes express TNFr1 to a significantly greater extent compared 
to classical and non-classical monocytes (Hijdra et al., 2012). It is therefore possible that the 
change in TNFr1 expression previously reported by our laboratory occurred in intermediate 
CD14++ CD16+ monocytes rather than CD14++CD16- classical monocytes. Nevertheless, 
examinations of temporal changes in the expression of TNFr1 on monocytes following resistance 
exercise are lacking.   
Our results indicate that circulating MCP-1 is also rapidly increased following damaging 
resistance exercise. Under inflammatory conditions, MCP-1 is the primary cytokine involved in 
mediating classical monocyte chemotaxis (Charo & Ransohoff, 2006; B. Lu et al., 1998; Rossi & 
Zlotnik, 2000; Shireman et al., 2006; Shireman et al., 2007; M. Takahashi et al., 2009). Relative 
to baseline, MCP-1 was significantly elevated at all post-exercise time points, and this response 
was similar between HVY and VOL. This is consistent with the reports indicating that 
circulating concentrations of MCP-1 parallel early inflammation (Shireman et al., 2006), and 
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suggests that both HVY and VOL protocols likely resulted in a significant recruitment of 
monocytes.  
To our knowledge, only one other study has examined changes in plasma MCP-1 in 
conjunction with an acute bout of resistance exercise (Ihalainen et al., 2014). In contrast to our 
findings, Ihalainen and colleagues (2014) report a significant decrease in plasma MCP-1 
concentrations, following an acute bout of high-volume leg press exercise [5 x 10 (80% 1RM)] 
in healthy untrained males. Data regarding the effect of training status on the plasma MPC-1 
response is currently lacking. However, differences between findings could be related to the 
magnitude of the exercise stimulus. We utilized an exercise protocol consisting of 5 exercises 
designed to target the entire lower extremity. In contrast, Ihalainen and colleagues utilized only 
the leg press exercise. Given the large disparity in total work between studies, it is possible that a 
minimal exercise volume may be required to stimulate MCP-1, and that this was not attained 
with the leg press alone. Nevertheless, Ihalainen and colleagues only examined plasma MCP-1 
concentrations up to 30 minutes post-exercise. Therefore, a delayed increase in plasma MCP-1 
cannot be discounted. 
Consistent with our findings, significant changes in plasma MCP-1 have been reported 
following a number of aerobic exercise interventions (Crystal, Townson, Cook, & LaRoche, 
2013; Peake, Suzuki, Hordern et al., 2005). Peake et al. (2005) observed significant increases in 
plasma MCP-1 immediately, and 1 hour post-exercise, following three separate running 
protocols of varying intensity (Peake et al., 2005). Similarly, Crystal et al. (2013) observed a 
significant increase in plasma MCP-1 immediately, 1 hour, and 6 hours post-exercise, following 
40 minutes of downhill running at 60% VO2max. Comparisons between aerobic exercise protocols 
appear to suggest that the MCP-1 response is related to exercise intensity (%VO2max) rather than 
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the degree of muscle damage (Peake et al., 2005). This is consistent with reports that plasma 
MCP-1 concentrations are higher following level running at 85% VO2max, despite a significantly 
lower plasma concentration of myoglobin compared to downhill running (Peake, Suzuki, Wilson 
et al., 2005; Peake et al., 2005). Anecdotally, our findings appear to support this notion, since 
MCP-1 trended (p = 0.074) towards being higher following high-volume resistance exercise 
compared to the more damaging high-intensity protocol. Nevertheless, changes in MCP-1 were 
not significantly different between trials. Collectively, it appears that exercise of a sufficient 
magnitude results in a rapid elevation in plasma MCP-1. This is likely in response to a 
disturbance in tissue homeostasis (Soehnlein & Lindbom, 2010), which may or may not be 
related to the degree of muscle damage. Further research is required to fully elucidate the effects 
of exercise on the magnitude of the MCP-1 response. 
MCP-1 exerts its chemotactic function via exclusive binding to the G-protein coupled 
receptor CCR2 (Rot & von Andrian, 2004). Our result indicate that CCR2 expression is 
significantly down-regulated at all post-exercise time points following both high-intensity and 
high-volume resistance exercise. The observed findings may be the result of agonist mediated 
receptor internalization, which is a well characterized mechanism contributing to the tight 
control of inflammation (Bennett, Fox, & Signoret, 2011; Berchiche, Gravel, Pelletier, St-Onge, 
& Heveker, 2011; Kelly, Bailey, & Henderson, 2008; Rot & von Andrian, 2004). However, to 
the best of our knowledge, no other study has evaluated changes in CCR2 expression following 
an acute bout of resistance exercise.  
Changes in CCR2 expression have been reported following examinations of MCP-
1/CCR2 mediated monocyte chemotaxis in vitro (Arai, Monteclaro, Tsou, Franci, & Charo, 
1997; Franci, Gosling, Tsou, Coughlin, & Charo, 1996; Handel et al., 2008). Handel and 
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colleagues (2008) observed a dose-dependent decrease in CCR2 expression following incubation 
of murine monocytes with MCP-1. A substantial down-regulation of CCR2 receptors was 
apparent within 30 minutes, while one hour of incubation was sufficient to induce a 60% down-
regulation of CCR2 receptors. Upon removal of the MCP-1 ligand, CCR2 expression began to 
recover. Nevertheless, maximal receptor expression was not regained for an additional 4 hours. 
Consistent with this, low nanomolar concentrations of MCP-1 have been shown to be sufficient 
to induce a substantial down-regulation of CCR2. Further, this effect was achieved within 5 to 10 
minutes of MCP-1 exposure (Franci et al., 1996). Together, these results suggest that MCP-1 
may induce the internalization of CCR2 receptors, possibly as part of a mechanism designed to 
modulate the magnitude of the monocyte response.  
A recent investigation by Volpe and colleagues (2012) indicates that internalization of 
CCR2 does not reduce the responsiveness of monocytes to MCP-1 (Volpe et al., 2012). These 
investigators suggest that following interaction with MCP-1, internalized receptors rapidly 
recycle back to the cell surface in order to maintain the responsiveness of the cell towards the 
chemokine. Physiologically, this action provides for continuous signaling from receptors at the 
leading edge of the monocyte, which is required for directional migration. This mechanism 
would allow monocytes to proceed along an increasing chemokine gradient without becoming 
desensitized. Nevertheless, under conditions of continuous stimulation, receptor cycling may still 
lead to a decrease in CCR2 receptor expression. However, given the need to maintain cell 
polarity, it is likely that that this response would be limited to a particular threshold, rather than 
being dose-dependent. This is consistent with the plateau observed in the present study, and may 
also explain why we did not find a significant inverse relationship between plasma MCP-1 
concentrations and CCR2 expression.  
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Cortisol has been shown to modulate the expression of CCR2 on human monocytes in 
vitro (Okutsu et al., 2008; Penton-Rol et al., 1999; Pettersson et al., 2005). Despite a significant 
increase in plasma cortisol following the high-volume protocol, changes in the expression of 
CCR2 were not different between trials. Additionally, changes in GCR expression were not 
different from BL, and were similar between the two acute protocols. Consequently, our results 
do not support the in vitro observations of others. It is worth mentioning however, that at least 4-
6 hours of incubation were required before an up-regulation of CCR2 was observed in vitro 
(Okutsu et al., 2008; Penton-Rol et al., 1999). Further, 60 minutes of cycling at 70% VO2peak was 
unable to stimulate an up-regulation of CCR2 on monocytes in vivo, even following 24 hours of 
additional incubation time (Okutsu et al., 2008). In the present study, plasma cortisol 
concentrations did not correlate with any outcome measure to a physiologically meaningful 
degree.  
CD11b mediates monocyte intravascular crawling, which is the direct pre-requisite to 
trans-endothelial migration (Ley et al., 2007; Sumagin et al., 2010). Our results indicate a 
moderate but significant up-regulation in CD11b at 1H post-exercise. Further, this change was 
similar between high-intensity and high-volume trials. The up-regulation of CD11b at 1H post-
exercise indicates a greater potential for monocyte adhesion, and is consistent with the temporal 
appearance of monocytes at sites of tissue damage reported by McLennan (McLennan, 1996). 
We have previously reported similar increases in CD11b on CD14++ monocytes following acute 
bouts of high-volume resistance exercise in well-trained males (Gonzalez et al., 2014; Jajtner et 
al., 2014). Our reports appear to be consistent with the findings of others (Hong & Mills, 2008; 
Jordan et al., 1999). Hong et al. (2008) observed a significant increase in the expression of 
CD11b on CD14++CD16- monocytes immediately, and 10-minutes post-exercise, following a 20-
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minute bout of moderate treadmill exercise at 65-70% VO2peak (Hong & Mills, 2008). In another 
study, a significant up-regulation in CD11b expression was observed following maximal 
treadmill exercise and marathon running, albeit on granulocytes (Jordan et al., 1999). 
Interestingly, a bout of moderate treadmill exercise was not sufficient to cause an up-regulation 
in CD11b (Jordan et al., 1999). This could indicate that exercise must be of a sufficient volume 
and/or intensity for CD11b expression to be increased.  
The observed increase in CD11b expression correlated moderately with plasma 
concentrations of both TNFα, and MCP-1 at 1H. These findings are supported by a number of in 
vitro and in situ studies, suggesting that both observations could be physiologically meaningful 
(Montecucco et al., 2008; Starikova et al., 2010; Sumagin et al., 2010; K. Takahashi et al., 2003; 
van Royen et al., 2003). However, TNFα and MCP-1 were also highly correlated with each other 
at all post-exercise time points (data not shown), suggesting that the association of at least one of 
these ligands with CD11b up-regulation is spurious. Previous work by Campbell et al. (2000) 
indicates that for a given receptor, the signals required for rapid adhesion to vascular integrin 
ligands are different from those required for chemotaxis, illustrating that two distinct G-protein-
linked receptor-dependent events are required for leucocyte extravasation from the blood 
(Campbell, Foxman, & Butcher, 1997). This suggests that TNFα mediated up-regulation of 
CD11b is more likely, since MCP-1 mediates chemotaxis. Nevertheless, we are unable to 









The present study investigated the acute pro-inflammatory response following two typical 
lower-body resistance exercise protocols in experienced, resistance trained men. Markers of 
muscle damage were elevated to a significantly greater extent in HVY, while plasma cortisol 
concentrations were significantly greater following VOL. Nevertheless, changes in plasma 
concentrations of TNFα, and MCP-1 were similar between HVY and VOL, as was the temporal 
response of TNFr1, CCR2, GCR and CD11b receptors on CD14++ CD16- monocytes. 
Consequently, our results do not support a role for cortisol in the modulation of these receptors 
in vivo, while the degree of muscle damage does not appear to influence plasma concentrations 
of TNFα, or MCP-1. It is therefore likely that both HVY and VOL protocols constitute an 
exercise stimulus that is sufficient enough to promote a robust pro-inflammatory response, which 
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